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INTRODUCTION 
Oral delivery of drugs is by far the most preferred route of drug delivery due to ease 
of administration, patient compliance and flexibility in formulation.Conventional oral dosage 
forms provide a specific drug concentration in systemic circulation without offering any 
control over drug delivery(1).These systems achieve as well as maintain drug concentration 
within therapeutically effective range needed for treatment only when taken several times a 
day. This results in significant fluctuation in drug levels.Now-a-days most of the 
pharmaceutical scientists are involved in developing an ideal drug delivery system (DDS). 
An ideal oral drug delivery system should steadily deliver a measurable and reproducible 
amount of drug to the target site over a prolonged period. Oral route has been the most 
popular and successfully used for sustained delivery of drugs because of convenience and 
ease of administration, greater flexibility in dosage form design and ease of production and 
low cost of such a system. (2) 
Controlled Drug Delivery Systems: 
Controlled drug delivery is one which delivers the drug at a predetermined rate, 
locally or systemically, for a specified period of time. Continuous oral delivery of drugs at 
predictable and reproducible kinetics for pre determined period throughout the course of GIT. 
Recently, a new generation of pharmaceutical products, called controlled release drug 
delivery systems, such as those developed from the osmotic pressure activated drug delivery 
system, have recently received regulatory approval for marketing, and their pharmaceutical 
superiority and clinical benefits over the sustained release and immediate release 
pharmaceutical products have been increased (3). 
Controlled release drug administration means not only prolongation of the duration of 
drug delivery, similar to the objective in sustained release and prolonged release, but the term 
also implies the predictability and reproducibility of drug release kinetics. The basic rationale 
of controlled drug delivery system is to optimize the biopharmaceutical, pharmacokinetics 
and pharmacodynamic properties of drug in such a way that its utility is maximized through 
reduction in the side effects and cure or control of condition in the shortest possible time by 
the most suitable route. 
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Controlled release denotes that the system is able to provide some actual therapeutic 
control, whether this is of a temporal nature, spatial nature, or both. Controlled drug delivery 
occurs when a polymer is combined with a drug or active agent such that the release from the 
bulk material is pre-designed. 
Controlled drug delivery systems have been developed which are capable of 
controlling the rate of drug delivery, sustaining the duration of therapeutic activity and/or 
targeting the delivery of drug to a tissue. 
Controlled drug delivery or modified drug delivery systems are conveniently divided 
into four categories: 
 Delayed release 
 Sustained release 
 Site-specific targeting 
 Receptor targeting 
More precisely, Controlled delivery can be defined as (4). 
1. Sustained drug action at a predetermined rate by maintaining a relatively constant, 
effective drug level in the body with concomitant minimization of undesirable side 
effects. 
2. Localized drug action by spatial placement of a controlled release system adjacent to 
or in the diseased tissue. 
3. Targeted drug action by using carriers or chemical derivatives to deliver drug to a 
particular target cell type. 
4. Provide a physiologically/therapeutically based drug release system. In other words, 
the amount and the rate of drug release are determined by the physiological/ 
therapeutic needs of the body. 
A controlled drug delivery system is usually designed to deliver the drug at particular 
rate. Safe and effective blood levels are maintained for a period as long as the system 
continues to deliver the drug. Controlled drug delivery usually results in substantially 
constant blood levels of the active ingredient as compared to the uncontrolled fluctuations 
observed when multiple doses of quick releasing conventional dosage forms are administered 
to a patient. 
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Advantages of Controlled Drug Delivery System: (5) 
 Avoid patient compliance problems. 
 Dosage frequency was reduced. 
 Minimize or eliminate local side effects. 
 Minimize or eliminate systemic side effects. 
 Obtain less potentiating or reduction in drug activity with chronic use. 
 Minimize drug accumulation with chronic dosing. 
 Improve efficiency in treatment. 
 Cures or controls condition more promptly. 
 Improves control of condition i.e., reduced fluctuation in drug level. 
 Improves bioavailability of some drugs. 
 Make use of special effects, eg., Sustained-release aspirin for morning relief of 
arthritis by dosing before bedtime. 
Economy i.e. reduction in health care costs. The average cost of treatment over an 
extended time period may be less, with less frequency of dosing, enhanced therapeutic 
benefits and reduced side effects. The time required for health care personnel to dispense and 
administer the drug and monitor patient is also reduced. 
Disadvantages of Controlled Drug Delivery System: 
Decreased systemic availability in comparison to conventional dosage forms, which 
may be due to incomplete release, increased first-pass metabolism, increased instability, 
insufficient residence time for complete release, site specific absorption, pH dependent 
stability etc.Poor in vitro – in vivo correlation. 
Possibility of dose dumping due to food, physiologic or formulation variables or 
chewing or grinding of oral formulations by the patient and thus, increased risk of toxicity. 
Retrievals of drug are difficult in case of toxicity, poisoning or hypersensitivity reactions. 
Reduced potential for dosage adjustment of drugs normally administered in varying strengths. 
Oral Controlled Drug Delivery Systems: 
Oral controlled release drug delivery is a drug delivery system that provides the 
continuous oral delivery of drugs at predictable and reproducible kinetics for a predetermined 
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period throughout the course of GI transit and also the system that target the delivery of a 
drug to a specific region within the GI tract for either local or systemic action. 
All the pharmaceutical products formulated for systemic delivery via the oral route of 
administration, irrespective of the mode of delivery (immediate, sustained or controlled 
release) and the design of dosage form (solid dispersion or liquid), must be developed within 
the intrinsic characteristics of GI physiology. Therefore the scientific framework required for 
the successful development of oral drug delivery systems consists of basic understanding of 
 Physicochemical, pharmacokinetic and pharmacodynamic characteristics of the drug. 
 The anatomic and physiologic characteristics of the gastrointestinal tract. 
Physicochemical characteristics and the drug delivery mode of the dosage form to be 
designed. 
The main areas of potential challenge in the development of oral controlled drug 
delivery systems are: - 
 Development of a drug delivery system: To develop a viable oral controlled release 
drug delivery system capable of delivering a drug at a therapeutically effective rate to 
a desirable site for duration required for optimal treatment. 
 Modulation of gastrointestinal transit time: To modulate the GI transit time so that the 
drug delivery system developed can be transported to a target site or to the vicinity of 
an absorption site and reside there for a prolonged period of time to maximize the 
delivery of a drug dose. 
 Minimization of hepatic first pass elimination: If the drug to be delivered is subjected 
to extensive hepatic first-pass elimination, preventive measures should be devised to 
either bypass or minimize the extent of hepatic metabolic effect. 
Conventional oral controlled dosage forms suffer from mainly two adversities. The 
short gastric retention time (GRT) and unpredictable gastric emptying time (GET). A 
relatively brief GI transit time of most drug products impedes the formulation of single daily 
dosage forms. 
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Altering the gastric emptying can overwhelm these problems. Therefore it is 
desirable, to formulate a controlled release dosage form that gives an extended GI residence 
time. 
 Extended release dosage form with prolonged residence time in stomach are highly 
desirable for drugs. 
 Those are locally active in stomach. 
 Those have an absorption window in the stomach or in the upper small intestine. 
 Those are unstable in the intestinal or colonic environment. 
 Have low solubility at high pH values. 
Extended Drug Delivery System: 
Extended release formulation is an important program for new drug research and 
development to meet several unmet clinical needs. There are several reasons for 
attractiveness of these dosage forms provides increase bioavailability of drug product, 
reduction in the frequency of administration to prolong duration of effective blood levels, 
reduces the fluctuation of peak trough concentration and side effects and possibly improves 
the specific distribution of the drug (6).  
Extended release drug delivery system achieves a slow release of the drug over an 
extended period of time or the drug is absorbed over a longer period of time. Extended 
release dosage form initially releases an adequate amount of drug to bring about the 
necessary blood concentration (loading dose, DL) for the desired therapeutic response and 
therefore, further amount of drug is released at a controlled rate (maintenance dose, DM) to 
maintain the said blood levels for some desirable period of time (7). 
Oral extended release drug delivery system: 
The oral extended release dosage forms offer the opportunity to provide constant or 
nearly constant drug plasma levels over an extended period of time following administration. 
Extended release DDS include single-unit, such as tablets or capsules, and multiple-unit 
dosage forms, such as mini tablets, pellets, beads or granules, either as coated (reservoir) or 
matrix devices. 
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Objectives of Extended Release Drug Delivery System: 
Every novel drug delivery system had a rationale for developing the dosage form 
likewise, ERDDS also having some objectives that are discussed below: 
Suitable Drug Candidate for Extended Release Drug Delivery System: 
The drugs that have to be formulated as an ERDDS should meet following parameters. 
 It should be orally effective and stable in GIT medium. 
 Drugs that have short half-life, ideally a drug with half-life in the range of 2 – 
4hrsmakes a good candidate for formulation into ER dosage forms Eg. Captopril, 
Salbutamol Sulphate. 
 The dose of the drug should be less than 0.5g as the oral route is suitable for drugs 
given in dose as high as 1.0g Eg. Metronidazole. 
 Therapeutic range of the drug must be high. A drug for ERDDS should have 
therapeutic range wide enough such that variations in the release do not result in 
concentration beyond the minimum toxic levels14. 
Factors Affecting the Extended Release Drug Delivery System: (7) 
Physiochemical Properties: 
Aqueous Solubility: 
Certain drug substance having low solubility is reported to be 0.1 mg/ml. As the drug 
must be in solution form before absorption, drug having low aqueous solubility usually 
suffers oral bioavailability problem due to limited GI transit time of un dissolved drug and 
limited solubility at absorption site. So these types of drug are undesirable to be formulated as 
extended release drug delivery system. Drug having extreme aqueous solubility are 
undesirable for extended release because, it is too difficult to control release of drug from the 
dosage form. 
Partition Co-efficient: 
As biological membrane is lipophilic in nature through which the drug has topass, so 
partition co-efficient of drug influence the bioavailability of drug very much. Drug having 
lower partition co-efficient values less than the optimum activity are undesirable for oral ER 
drug delivery system, as it will have very less lipid solubility and the drug will be localized at 
the first aqueous phase it come in contact. Drughaving higher partition co-efficient value 
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greater than the optimum activity are undesirable for oral ER drug delivery system because 
more lipid soluble drug will not partition out of the lipid membrane once it gets in the 
membrane. 
Protein Binding: 
The Pharmacological response of drug depends on unbound drug concentration rather 
than total concentration and all drugs bound to some extent to plasma or tissue proteins. 
Proteins binding of drug play a significant role in its therapeutic effect regardless the type of 
dosage form as extensive binding to plasma increase biological half-life and thus, such type 
of drug will release up to extended period of time then there is no need to develop extended 
release drug delivery for this type of drug. 
Drug Stability: 
As most of ER Drug delivery system is designing to release drug over the length of 
the GIT, hence drug should be stable in GI environment. So drug, which is unstable, can‟t be 
formulated as oral ER drug delivery system, because of bioavailability problem. 
Mechanism and Site of Absorption: 
Drug absorption by carrier mediated transport and those absorbed through a window 
are poor candidate for oral ER drug delivery system. Drugs absorbed by passive diffusion, 
pore transport and through over the entire length of GIT are suitable candidates for oral ER 
drug delivery system. 
Dose size: 
If a product has dose size > 0.5g it is a poor candidate for ER drug delivery system, 
because increase in bulk of the drug, thus increases the volume of the product. Thus dose of 
drug should small to make a good drug candidate for extended release drug delivery system. 
Biological Properties: 
Absorption: 
The absorption behavior of a drug can affect its suitability as an extended release 
product. The aim of formulating an extended release product is to place a control on the 
delivery system. It is essential that the rate of release is much slower the rate of absorption. If 
we assume the transit time of most drugs and devices in the absorptive areas of GI tract is 
about 8-12 hours, the maximum half-life for absorption should be approximately 3-4 hours. 
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Otherwise the device will pass out of absorptive regions before drug release is complete. 
Therefore the compounds with lower absorption rate constants are poor candidates for 
extended release systems. Some possible reasons for a low extent of absorption are poor 
water solubility, small partition co-efficient, acid hydrolysis, and metabolism or its site of 
absorption. 
Distribution: 
The distribution of drugs in tissues can be important factor in the overall drug 
elimination kinetics. Since it not only lowers the concentration of circulating drug but it also 
can be rate limiting in its equilibrium with blood and extra vascular tissue, consequently 
apparent volume of distribution assumes different values depending on time course of drug 
disposition. Drugs with high apparent volume of distribution, which influence the rate of 
elimination of the drug, are poor candidate for oral ER drug delivery system e.g. 
Chloroquine. For design of extended release products, one must have information on 
disposition of the drug. 
Metabolism: 
Drug, which extensively metabolized is not suitable for ER drug delivery system. A 
drug capable of inducing metabolism, inhibiting metabolism, metabolized at the site of 
absorption or first-pass effect is poor candidate for ER delivery, since it could be difficult to 
maintain constant blood level e.g. levodopa, nitroglycerine. Drugs that are metabolized 
before absorption, either in lumen or the tissues of the intestine, can show decreased 
bioavailability from the extended releasing systems. Most intestinal walls are saturated with 
enzymes. As drug is released at a slow rate to these regions, lesser drug is available in the 
enzyme system. Hence the systems should be devised so that the drug remains in that 
environment to allow more complete conversion of the drug to its metabolite. 
Half-life of Drug: 
A drug having biological half-life between 2 to 8 hours is best suited for oral ER drug 
delivery system. As if biological half-life < 2hrs the system will require unacceptably large 
rate and large dose and biological half-life> 8hrs formulation of such drug into ER drug 
delivery system is unnecessary. 
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Pharmacokinetic parameters: (8) 
Elimination half-life (t ½): 
Drugs having a t ½ and 8 hours are ideally suited for CRDDS. If the t ½ is less than 1 
hour the dose size required to be incorporated for a 12 hour or 24 hour duration dosage form 
may be too large. If the t ½ is very long there is usually no need for a CRDDS, unless it is 
simply intended for a reduction in fluctuation of steady state blood levels. 
Total clearance (CL): 
CL is a measure of the volume of distribution cleared of drug per unit of time. It is the 
key parameter in estimating the required dose rate for CRDDS, and predicting the steady 
state concentration. 
Terminal disposition rate constant (Ke or λz): 
The terminal disposition rate constant or elimination rate constant can be obtained 
from the t ½ and is required to predict a blood level time profile. 
Apparent volume of distribution (Vd): 
The Vd is the hypothetical volume of a drug would occupy if it were dissolved at the 
same concentration as that found in blood. It is the proportionality constant relating the 
amount of drug in the body to the measured concentration in the blood. Among the trio CL, 
Vd, and t½, the former two parameters are the independent variables and the last one is the 
dependent variable. The Vd or CL is required to predict the concentration time profile. 
Absolute bioavailability (F): 
The absolute bioavailability is the percentage of drug taken up into systemic 
circulation upon extra vascular administration. For drugs to be suitable for CRDDS one wants 
an F value to be close to 100%. 
Intrinsic absorption rate constant (Ka): 
The intrinsic absorption rate constant of the drug administered per oral in the form of 
a solution should be high, generally by an order of magnitude higher than the desired release 
rate constant of the drug from the dosage form, in order to insure that release process is the 
rate controlling step. 
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Therapeutic concentration (Css): 
The therapeutic concentrations are the desired or target steady state peak 
concentrations (Css max), the desired or target steady state minimum concentrations (Css 
min), and the mean steady state concentration (Css.avg). The difference between Css max 
and Css min is the fluctuation. The smaller the desired fluctuation the greater must be the 
precision of the dosage form performance. The lower Css, the smaller Vd, the longer t½, the 
higher F and The less amount of drug is required to be incorporated into a CRDDS. 
In vitro In vivo correlation: (9, 10) 
In vitro-in vivo correlation plays a key role in the drug development and optimization 
of formulation. The in vitro release data of a dosage form containing the active substance 
serve as characteristic in vitro property, while the in vivo performance is generally 
represented by the time course of the plasma concentration of the active substance. These in 
vitro and in vivo data are then treated scientifically to determine correlations. For oral dosage 
forms, the in vitro release is usually measured and considered as dissolution rate. The 
relationship between the in vitro and in vivo characteristics can be expressed mathematically 
by a linear or nonlinear correlation. However, the plasma concentration cannot be directly 
correlated to the in vitro release rate; it has to be converted to the in vivo release or 
absorption data, either by pharmacokinetic compartment model analysis or by linear system 
analysis. 
Advantages of Extended release dosage forms: 
 The extended release formulations may maintain therapeutic concentrations over 
prolonged periods. 
 The use of extended release formulations avoids the high blood concentration. 
 Extended release formulations have the potential to improve the patient compliance. 
 Reduce the toxicity by slowing drug absorption. 
 Increase the stability by protecting the drug from hydrolysis or other derivative 
changes in gastrointestinal tract. 
 Minimize the local and systemic side effects. 
 Improvement in treatment efficacy. 
 Minimize drug accumulation with chronic dosing. 
 Usage of less total drug. 
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 Improvement the bioavailability of some drugs. 
 Improvement of the ability to provide special effects. 
Ex: Morning relief of arthritis through bed time dosing. 
Disadvantages of Extended release dosage forms: 
 High cost of preparation. 
 The release rates are affected by various factors such as, food and the rate transit 
through the gut. 
 Some differences in the release rate from one dose to another dose but these have 
been minimized by modern formulations. 
 Extended release formulation contains a higher drug load and thus any loss of 
integrity of the release characteristics of the dosage form. 
 The larger size of extended release products may cause difficulties in ingestion or 
transit through gut. 
SUSTAINED DRUG DELIVERY SYSTEMS (SDDS) 
Time release technology, also known as sustained – release, sustained – action, 
extended – release, time – release or timed – release, controlled – release, modified release, 
or continuous – release, is a mechanism used in pill tablets or capsules to dissolve slowly and 
release a drug over time. The advantages of sustained – release tablets or capsules are that 
they can often be taken less frequently than immediate - release formulations of the same 
drug, and that they keep steadier levels of the drug in the bloodstream (11). 
Sustained release tablets and capsules are commonly taken only once or twice daily, 
compared with their counterpart, conventional forms that may have to be taken three or four 
times daily to achieve the same therapeutic effect. Typically, sustained release products 
provide an immediate release of drug that promptly produces the desired therapeutic effect, 
followed by gradual release of additional amounts of drug to maintain this effect over a 
predetermined period. 
The basic rationale of a sustained drug delivery system is to optimize the 
biopharmaceutical, pharmacokinetic and pharmacodynamic properties of a drug in such a 
way that its utility is maximized through reduction in side effects and cure or control of 
condition in the shortest possible time by using smallest quantity of drug, administered by the 
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most suitable route. The goal of sustained drug delivery system is to provide a therapeutic 
amount of drug to the proper site in the body to achieve promptly and then maintain the 
desired drug concentration for a prolonged period of time. (12) 
Advantages of sustained release dosage forms 
a) Patient Compliance: Lack of compliance is generally observed with long term treatment 
of chronic disease, as success of drug therapy depends upon the ability of patient to 
comply with the regimen. The problem of lack of patient compliance can be resolved to 
some extent by administering SDDS. 
 
b) Reduced 'see - saw' fluctuation: Administration of a drug in a conventional dosage form 
[except via intravenous infusion at a constant rate] often results in 'see – saw' pattern of 
drug concentration in the systemic circulation and tissue compartments depending on 
drug kinetics such as the rate of absorption, distribution, elimination and dosing intervals. 
A well designed sustained release drug delivery system can significantly reduce the 
frequency of drug dosing and also maintain a steadier drug concentration in blood 
circulation and target tissue cells. 
 
c) Reduced total dose: SDDS have repeatedly been shown to use less amount of total drug to 
treat a diseased condition. By reducing the total amount of drug, decrease in systemic or 
local side effects are observed. This would also lead to greater economy. 
 
d) Improved efficiency in treatment: Optimal therapy of a disease requires an efficient 
delivery of active drugs to the tissues, organs that need treatment. Very often doses far in 
excess to those required in the cells have to be administered in order to achieve the 
necessary therapeutically effective concentration. This leads to undesirable, toxicological 
and immunological effects in non-target tissue. A controlled release dosage forms leads to 
better management of the acute or chronic disease condition. 
 
e) Economy: In comparison with conventional dosage forms the average cost of treatment 
over an extended period may be less. Economy also may result from a decrease in nursing 
time and hospitalization. Safety margin of high potency drugs can be increased. 
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f) Improved therapy: 
 Sustained blood level: The dosage form provides uniform drug availability / blood 
levels unlike peaks and valley pattern obtained by intermittent administration. 
 
 Attenuation of adverse effects: The incidence and intensity of undesirable effects 
caused by excessively high peak drug concentration resulting from the administration 
of conventional dosage forms is reduced. 
 
 It is seldom that a dose is missed because of non-compliance by the patient. 
Disadvantages of Sustained Release Dosage Forms 
a) Dose dumping: Dose dumping is a phenomenon where by relatively large quantities of 
drug in a sustained release formulation is rapidly released, introducing potential toxic 
quantities of the drug into the systemic circulation. Dose dumping can lead to fatalities in 
case of potent drug, which have a narrow therapeutic index e.g. Phenobarbital 
 
b) Less flexibility in accurate dose adjustment: In conventional dosage forms, dose 
adjustments are much simpler e.g. tablet can be divided into two fractions. In case of 
SDDS, this appears to be much more complicated. Controlled release property may get 
lost, if dosage form is fractured. 
 
c) Poor in vitro – in vivo correlation: In SDDS, the rate of drug release is deliberately 
reduced to achieve drug release possibly over a large region of gastrointestinal tract. Here 
the so called „Absorption window‟ becomes important and may give rise to unsatisfactory 
drug absorption in vivo despite excellent in-vitro release characteristics. 
 
d) Patient variation: The time period required for absorption of drug released from the 
dosage form may vary among individuals. Co-administration of other drugs, presence or 
absence of food and residence time in gastrointestinal tract is different among patients. 
This also gives rise to variation in clinical response among the patient. 
Designing of sustained release drug delivery system 
Most of the orally administered drugs, targeting is not a primary concern and it is 
usually intended for drugs to penetrate to the general circulation and perfuse to other body 
tissues. For this reason, most systems employed are of the sustained release variety. It is 
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assumed that increasing concentration at the absorption site will increase circulating blood 
levels, which in turn, promotes greater concentration of drug at the site of action. If toxicity is 
not an issue, therapeutic levels can thus be extended. 
These dosage forms must function in an environment of changing pH, the stomach 
being acidic and the small intestine more neutral, the effect of pH on the release process must 
be defined. 
a) Partition Coefficient: The partition coefficient is an important drug property, which 
influences the design of oral SDDS as it governs the permeation of drug particles through 
biological membrane and diffusion of drug molecules across rate controlling membranes. 
Compounds which are lipophilic in nature having high partition coefficient are poorly 
aqueous soluble and retained in the lipophilic tissue for a longer time and vice versa. The 
choice of diffusion – limiting membranes must largely depend on the partitioning 
characteristics of the drug. 
 
b) Drug stability: The stability of the drugs at the site of its release and exposure bio-milieu 
is one more drug property that can influence the design of oral controlled drug delivery. 
Drugs that are unstable in gastric pH can be developed as slow release dosage form and 
drug release can be delayed till the dosage form reaches the intestine. Drugs that undergo 
gut-wall metabolism and show instability in small intestine are not suitable for controlled 
drug delivery systems. Orally administered drugs can be a subject to both acid-base 
hydrolysis and enzymatic degradation. Degradation will proceed at a reduced rate for 
drugs in solid state; therefore, this is the preferred composition of delivery for problem 
cases.  
 
c) Absorption: The rate, extent and uniformity of absorption of a drug are important factors 
when considering its formulation into a sustained – release system. Since the rate limiting 
step in drug delivery from a SDDS is its release from a dosage form, rather than 
absorption, a rapid rate of absorption of drug relative to its release is essential if system is 
to be successful. Since the purpose of forming a sustained release product is to place 
control on the delivery system, it is necessary that the rate of release is much slower than 
the rate of absorption. 
 
 
15 
d) Disease State: In some cases before the designing of an oral sustained delivery system for 
a drug it is important to consider the patient body condition and requirement. 
Characteristics of drugs unsuitable for oral sustained release forms 
a) Not effectively absorbed in the lower intestine e.g. riboflavin, ferrous salts 
b) Absorbed and excreted rapidly; short biologic half-lives (< 1hr) e.g. penicillin G 
c) Long biologic half-lives (>12 hr.) e.g. diazepam, phenytoin 
d) Large doses required (>1g) e.g. Sulfonamides 
e) Drugs with low therapeutic indices e.g. phenobarbital, digitoxin 
f) Precise dosage titrated to individual is required e.g. anticoagulants, cardiac glycosides 
g) No clear advantage for sustained release formulation e.g. Griseofulvin 
Criteria for choosing drugs for sustained release dosage forms 
a) Desirable half-life: The half-life of a drug is an index of its residence time in the body. If 
the drug has a short half-life (less than 2 hours), the dosage form may contain a 
prohibitively large quantity of the drug while drugs with elimination half-life of eight 
hours or more are sufficiently sustained in the body, when administered in conventional 
dosage from. SDDS is generally not necessary in such cases. Ideally, the drug should 
have half-life of three to four hours. Therapeutic compounds with short half-life are 
generally are excellent candidate for sustained-release formulations, as this can reduce 
dosing frequency. 
 
b) High therapeutic index: Drugs with low therapeutic index are unsuitable for incorporation 
in controlled release formulations. If the system fails in the body, dose dumping may 
occur, leading to fatalities e.g. Digitoxin. 
 
c) Small dose: If the dose of a drug in the conventional dosage form is high, its suitability as 
a candidate for sustained release is seriously undetermined. This is chiefly because the 
size of a unit dose sustained formulation will become too big to administer.. In general, a 
single dose of 0.5 - 1.0 g is considered maximal for a conventional dosage form. This also 
holds for sustained release dosage form. Another consideration is the margin of safety 
involved in administration of large amount of a drug with a narrow therapeutic range. 
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d) Desirable absorption and solubility characteristics: Absorption of poorly water soluble 
drug is often dissolution rate limited. Incorporating such compounds into controlled 
release formulations is therefore unrealistic and may reduce overall absorption efficiency. 
 
e) Desirable absorption window: Certain drugs when administered orally are absorbed only 
from a specific part of gastrointestinal tract. This part is referred to as the „absorption 
window‟. Drugs exhibiting an absorption window like fluorouracil, thiazide diuretics, if 
formulated as sustained release dosage form are unsuitable. 
 
f) First pass clearance: Delivery of the drug to the body in desired concentrations is 
seriously hampered in case of drugs undergoing extensive hepatic first pass metabolism, 
when administered in sustained release forms. 
COLON TARGETING DRUG DEIVERY SYSTEMS (CTDDS) 
Colonic delivery offers several potential therapeutic advantages as a site for drug delivery, 
 The colon is rich in lymphoid tissue, uptake of antigens into the mast cells of the 
colonic mucosa produces rapid local production of antibodies and this helps in 
efficient vaccine delivery. 
 The colon is attracting interest as a site where poorly absorbed drug molecule may 
have an improved bioavailability. 
 The colon has a longer retention time and appears highly responsive to agents that 
enhance the absorption of poorly absorbed drugs. 
 Reduced proteolytic activity in the colon may be helpful in achieving reasonable 
absorption of certain drugs that are enzymatically labile in small intestine. 
 Reduced fluid motility and motility in the colon when compared with small intestine 
is advantageous formulation consists of multiple components such as permeation 
enhancers that must reach epithelial layer to achieve close spatial proximity with each 
other. 
 The colonic region has somewhat less hostile environment with less diversity and less 
intensity of activity as compared to stomach and small intestine. (13-15) 
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Targeting of drugs to the colon is of increasing importance for local treatment of 
inflammatory bowel diseases (IBD) of the colon such as ulcerative colitis and crohn‟s disease 
(CD) and in treatment of colorectal cancers. Treatment might be more effective if the drug 
substances were targeted directly on the site of action in the colon. Lower doses might be 
adequate and, if so, systemic side effects might be reduced. A number of other serious 
diseases of the colon, e.g. colorectal cancer, might also be capable of being treated more 
effectively if drugs were targeted on the colon. Site-specific means of drug delivery could 
also allow oral administration of peptide and protein drugs, which normally become 
inactivated in the upper parts of the gastrointestinal tract. (16,17) 
Colonic drug delivery can be achieved by oral or rectal administration. With regard to 
rectal route, the drugs do not always reach the specific sites of the colonic disease and the 
sites of colonic absorption. To reach the colon and to be able to specifically deliver and 
absorb the drug there, the dosage form must be formulated taking into account the obstacles 
of gastrointestinal tract. (18,19) 
Factors to be considered in designing CTDDS 
Formulations for colonic delivery are, in general, delayed-released dosage forms 
which may be designed either to provide a „burst release‟ or a sustained / prolonged / 
targeted. 
Factors to be considered for designing CTDDS are explained below: 
(A) Anatomy and physiology of colon (20) 
The large intestine has 3 parts: the cecum, the colon, and the rectum. The main 
function of the large intestine is to remove water and salts (electrolytes) from the undigested 
material and to form solid waste (feces) that can be excreted. The remaining contents of the 
large intestine move to the rectum, where feces are stored until they leave the body through 
the anus as a bowel movement. 
In mammals colon is further subdivided into the ascending colon, transverse colon, 
the descending colon and the sigmoid colon. The colon from cecum to the mid transverse 
colon is also known as the right colon. The remainder is known as the left colon. The location 
of the parts of the colon is either in the abdominal cavity or behind it in the retro-peritoneum. 
The anatomy of colon is depicted by Fig. 1. 
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Figure: 1 Anatomy of Colon 
 Ascending colon: 
The ascending colon is on the right side of the abdomen. It is the part of the colon from 
the cecum to the hepatic flexure (the turn of the colon by the liver). It is retroperitoneal in 
most humans. In grazing animals the cecum empties into the spiral colon. 
 Transverse colon: 
The transverse colon is the part of the colon from the hepatic flexure to the splenic 
flexure. The transverse colon hangs off the stomach, attached to it by a wide band of tissue 
called the greater omentum. On the posterior side, the transverse colon is connected to the 
posterior abdominal wall by a mesentery known as the transverse mesocolon. As the path 
progresses from intestine the solid content increases as water gets absorbed. 
 Descending colon: 
The descending colon is the part of the colon from the splenic flexure to the beginning of 
the sigmoid colon. It is retroperitoneal in two-thirds of humans. In the other third, it has a 
(usually short) mesentery. 
 Sigmoid colon: 
The sigmoid colon is the part of the large intestine after the descending colon and before 
the rectum. The name sigmoid means S-shaped. The walls of the sigmoid colon are muscular, 
and contract to increase the pressure inside the colon, causing the stool to move into the 
rectum. 
 
19 
(B) pH of the colon (20) 
High pH gradient exists between the different parts of GIT. pH gradient between 
saliva and gastric juice and between gastric juice and intestinal juice is considerably high but 
that between different parts of intestine is low. The pH of the GIT is subject to both inter and 
intra subject variations. Diet, diseased state, and food intake influence the pH of the 
gastrointestinal fluid. The change in pH along the gastrointestinal tract has been used as a 
means for targeting drug to the colon. The pH of various sites is illustrated in Fig. 2. 
(C) Transit time to colon (20) 
Gastric emptying of dosage form is highly variable and depends primarily on whether 
subject is fed or fasted and on the properties of the dosage form such as size and density. 
Under normal conditions transit time to colon is between 5 to 7 h. But this transit time varies 
with fed and fasted state of GIT. Under fasted state transit time is between 3 to 5 h and in fed 
state it is between 6 to 10 h. The movement of materials through the colon is slow and tends 
to be highly variable and influenced by a number of factors other than diet like mobility, 
stress, disease state and presence of other drugs. 
 
Figure: 2 pH and transit time in GIT 
 
20 
(D) Colonic microflora (20) 
Intestinal enzymes are used to trigger drug release in various parts of the GIT. 
Usually, theses enzymes are derived from gut Microflora residing in high number in the 
colon. These facts and the bag shaped nature of the cecum make this site the favourite region 
for microbial settlement. Colon consists of a more than 500 different types of enzyme 
liberating symbiotic anaerobes. Enzymes derived from microbes are used to release drug 
from the polymeric coating and prodrugs. There is a vast difference in microflora count of 
intestine and cecum. The most important anaerobic bacteria are bacteroides, Bifidobacterium, 
Eubacterium, Peptococcus, Peptostreptocococcus, Ruminococcus, Propionibacterium and 
Clostridium. During illness and antibiotic therapy there is reversible destruction of microbes.  
Classification of CTDDS: 
CTDDS can be classified as follows: 
 pH dependent systems. 
 Time dependent systems. 
 Bacterial enzyme dependent system. 
 Covalent linkage of a drug with a carrier 
 Redox release system. 
 Bioadhesive systems. 
 Coating with micro particles. 
 Osmotic controlled drug delivery. 
pH dependent systems (21-23) 
The polymers used for colon targeting, however, should be able to withstand the 
lower pH values of the stomach and of the proximal part of the small intestine and also be 
able to disintegrate at the neutral or slightly alkaline pH of the terminal ileum and preferably 
at the ileocecal junction. These processes distribute the drug throughout the large intestine 
and improve the potential of CTDDS. 
Disadvantages of pH dependent systems 
Lack of consistency in the dissolution of polymer at the desired site. Moreover, many 
factors such as the presence of short chain fatty acids, residues of bile acids, carbon dioxide 
or other fermentation products can reduce the colonic pH to approximately 6 which can 
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certainly affect the release of drug in the colon. Certain disease state does alter the pH of the 
colon. 
Time dependent systems (20) 
Strategy of time released system is to resist the acidic environment of stomach and 
release the drug after predetermined lag time, after which release of drug take place. 
Disadvantages of time dependent systems: 
Individual to individual variation arises due to health, pathologic state, concomitant 
medication which causes Premature / Delayed drug release. 
Bacterial enzyme dependent system (20-24) 
The bio-environment inside the human GIT is characterized by the presence of 
complex microflora especially the colon that is rich in microorganisms that are involved in 
the process of reduction of dietary component or other materials. Drugs that are coated with 
the polymers, which are showing degradability due to the influence of colonic 
microorganisms, have been exploited in designing drugs for colon targeting. 
Actually, upon passage of the CTDDS through the GIT, it remains intact in the 
stomach and small intestine where very little microbially degradable activity is present that is 
quiet insufficient for cleavage of polymer coating. Release of the drugs from polysaccharide 
based formulation is supposed to take place after degradation of polysaccharide by the 
enzymes released from bacterial colonies present in the colonic microflora. Some of the 
enzymatic degradation of polysaccharides is given in table 1. 
Table:1 Microbial degradation of polysaccharides 
S. NO Polysaccharide Bacterial species that degrade polysaccharide 
1 Amylose Bacteroids, BIfidobacterium 
2 Chitosan BIfidobacterium 
3 Cyclodextran Bacteroids 
4 Guar gum Bacteroids, Ruminococcus 
5 Dextran Bacteroids 
6 Pectin Bacteroids, BIfidobacterium, Eubacterium 
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Covalent linkage of the drug with a carrier (20) 
It involves the formation of covalent linkage between drug and carrier in such a 
manner that upon oral administration the moiety remains intact in the stomach and small 
intestine. This approach chiefly involves the formation of prodrug, The problem of stability 
of certain drugs from the adverse environment of the upper GIT can be eliminated by prodrug 
formation. Site specific drug delivery through site specific prodrug activation may be 
accomplished by the utilization of some specific property at the target site. 
Redox sensitive polymers  
Under anaerobic conditions, bacterial azo reduction by enzymatically generated 
reduced flavins where the initial substrate thought to be involved in cellular electron transport 
requires the presence of NADPH as its electron source. As NADPH is oxidized, the electron 
mediator acts as an electron shuttle from the NADPH dependent flavoprotein to the azo 
compound. Reduction of the azo bond to the hydroazo intermediate requires a low electron 
density within the azo region, and thussubstitution of electron-withdrawing groups will favor 
this reaction. Redox potential is an expression of the total metabolic and bacterial activity in 
the colon and it is believed to be insensitive to dietary changes.  
The mean redox potential of 
 Proximal small bowl is - 67 90 mv, 
 Distal small bowl is -196 97 mv 
 Colon is -145 72 mv. 
Microflora-induced changes in the redox potential can also be used as a highly selective 
mechanism for targeting to the colon. 
Bioadhesive systems 
Oral administration of some drugs requires high local concentration in the large 
intestine for optimum therapeutic effects. Dissolution of dosage form and simultaneous 
absorption from upper GIT lead to low intra colonic drug concentration as well as absorption 
of drugs result in the generation of side effects. 
Bioadhesion is a process whereby drug remains in contact with a particular organ for 
a longer period of time. It may be used for improved absorption of poorly absorbable drugs. 
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Polymers: polycarbophils, polyurethanes and poloxamers.(25) 
Coating with microparticles (26) 
It consists of small silica particles (5-10 μm in diameter) covalently linked to a drug. 
Osmotic controlled drug delivery (OROS-CT) 
The OROS-CT (Alzacorporation) can be used to target the drug locally to the colon 
for the treatment of disease or to achieve systemic absorption that is otherwise unattainable. 
The OROS-CT system can be single osmotic unit or may incorporate as many as 5-6 push-
pull units each 4mm in diameter, encapsulated within a hard gelatin capsule. Each bilayer 
push pull unit contains an osmotic push layer and a drug layer, both surrounded by a 
semipermeable membrane. An orifice is drilled through the membrane next to the drug layer. 
Immediately after the OROS-CT is swallowed, the gelatin capsule containing the push-pull 
units dissolves. Because of its drug-impermeable enteric coating, each push-pull unit is 
prevented from absorbing water in the acidic aqueous environment of the stomach and hence 
no drug is delivered. As the unit enter the small intestine, the coating dissolve in this higher 
pH environment (pH >7), water enters the unit, causing the osmotic push compartment to 
swell and concomitantly creates a flowable gel in the drug compartment. Swelling of the 
osmotic push compartment forces drug gel out of the orifice at a rate precisely controlled by 
the rate of water transport through the semipermeable membrane. For treating ulcerative 
colitis, each push pull unit is designed with a 3-4 h post gastric delay to prevent drug delivery 
in the small intestine. 
Drug candidates suitable for colonic delivery 
Drug delivery selectively to the colon through oral route is becoming increasingly 
popular for the treatment of large intestinal diseases and for systemic absorption of peptides 
and protein drugs. The best Candidates for CTDDS are drugs which show poor absorption 
from the stomach or intestine including peptides. The drugs used in the treatment of IBD, 
ulcerative colitis, diarrhea, and colon cancer are ideal candidates for local colon delivery. 
Drug Carrier is another factor which influences CTDDS. The selection of carrier for 
particular drugs depends on the physiochemical nature of the drug as well as the disease for 
which the system is to be used. Factors such as chemical nature, stability and partition 
coefficient of the drug and type of absorption enhancer chosen influence the carrier selection. 
The choice of drug carrier depends on the functional groups of the drug molecule.(27) 
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The carriers, which contain additives like polymers (may be used as matrices and 
hydro gels or coating agents) may influence the release properties and efficacy of the 
systems. 
Because of small extent of paracellular transport, the colon is a more selective site for 
drug absorption than the small intestine. Drug shown to be well absorbed include 
glibenclamide, diclofenac, theophylline, ibuprofen, metoprolol, 5- flurouracil and oxprenolol. 
As dosage forms remain longer in the large intestine than in the small intestine, CTDDS 
could be used to prolong drug release. (28) 
Types of formulation for colon targeted drug delivery systems (29) 
Colon targeted drug delivery system have been classified into two types: 
a) Single unit CTDDS: It may suffer from the disadvantage of unintentional disintegration 
of the formulation due to manufacturing deficiency or unusual gastric physiology that 
may lead to drastically compromised systemic drug bioavailability or loss of local 
therapeutic action in the colon. 
 
b) Multiparticulate CTDDS: In comparison to single unit systems, these systems offer 
potential benefits, like increased bioavailability, reduced risk of systemic toxicity, 
reduced risk of local irritation and predictable gastric emptying. Multiparticulate 
approaches tried for colonic delivery includes formulations in the form of pellets, 
granules, microparticles and nanoparticles. Multiparticulate formulations enabled the drug 
to reach the colon quickly and were retained in the ascending colon for a relatively long 
period of time, as compared to single unit systems. Because of their smaller particle size 
as compared to single unit dosage forms these systems tend to be more uniformly 
dispersed in the GIT and also ensure more uniform drug absorption. 
COLORECTAL CANCER 
Cancer begins when cells in a part of the body start to grow out of control. There are 
many kinds of cancer, but they all start because of out-of-control growth of abnormal cells. 
Cancer cell growth is different from normal cell growth. Instead of dying, cancer cells 
continue to grow and form new, abnormal cells. In most cases the cancer cells form a tumor. 
Cancer cells can also invade (grow into) other tissues, something that normal cells cannot do. 
Growing out of control and invading other tissues are what makes a cell a cancer cell. Cells 
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become cancer cells because of damage to DNA. DNA is in every cell and directs all its 
actions. In a normal cell, when DNA is damaged the cell either repairs the damage or the cell 
dies. In cancer cells, the damaged DNA is not repaired, but the cell doesn't die like it should. 
Instead, this cell goes on making new cells that the body does not need. These new cells will 
all have the same damaged DNA as the first abnormal cell does. 
Colorectal cancer is a term used for cancer that starts in the colon or the rectum. 
These cancers can also be referred to separately as colon cancer or rectal cancer, depending 
on where they start. Colon cancer and rectal cancer have many features in common. 
Types of cancer in the colon and rectum (30) 
a) Adenocarcinomas: More than 95% of colorectal cancers are a type of cancer known as 
adenocarcinomas. These cancers start in cells that form glands that make mucus to lubricate 
the inside of the colon and rectum. When doctors talk about colorectal cancer, this is almost 
always what they are referring to. Other, less common types of tumors may also start in the 
colon and rectum. These include: 
b) Carcinoid tumors: These tumors start from specialized hormone-producing cells in the 
intestine. They are discussed in our document Gastrointestinal Carcinoid Tumors. 
c) Gastrointestinal stromal tumors (GISTs): These tumors start from specialized cells in 
the wall of the colon called the interstitial cells of Cajal. Some are benign (non-cancerous); 
others are malignant (cancerous). These tumors can be found anywhere in the digestive tract, 
but they are unusual in the colon. They are discussed in our document Gastrointestinal 
Stromal Tumors (GIST). 
d) Lymphomas: These are cancers of immune system cells that typically start in lymph 
nodes, but they may also start in the colon, rectum, or other organs. Information on 
lymphomas of the digestive system is included in our document Non-Hodgkin Lymphoma. 
e) Sarcomas: These tumors can start in blood vessels as well as in muscle and connective 
tissue in the wall of the colon and rectum. Sarcomas of the colon or rectum are rare. They are 
discussed in our document Sarcoma - Adult Soft Tissue Cancer. 
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Risk factors for colorectal cancer 
a) Lifestyle-related factors (30, 31) 
Several lifestyle-related factors have been linked to colorectal cancer. In fact, the links 
between diet, weight, and exercise and colorectal cancer risk are some of the strongest for 
any type of cancer. 
b) Personal history of inflammatory bowel disease (32) 
Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's 
disease, is a condition in which the colon is inflamed over a long period of time. People who 
have had IBD for many years often develop dysplasia. Dysplasia is a term used to describe 
cells in the lining of the colon or rectum that look abnormal (but not like true cancer cells) 
when seen with a microscope. These cells can change into cancer over time. 
c) Family history of colorectal cancer or adenomatous polyps (32) 
Most colorectal cancers occur in people without a family history of colorectal cancer. 
Still, as many as 1 in 5 people who develop colorectal cancer have other family members 
who have been affected by this disease. People with a history of colorectal cancer in one or 
more first-degree relatives (parents, siblings, or children) are at increased risk. The risk is 
about doubled in those with only one affected first-degree relative. It is even higher if that 
relative was diagnosed with cancer when they were younger than 45, or if more than one 
first-degree relative is affected. Reasons for the increased risk are not clear in all cases. 
Cancers can "run in the family" because of inherited genes, shared environmental factors, or 
some combination of these. 
d) Inherited syndromes (32) 
About 5% to 10% of people who develop colorectal cancer have inherited gene 
defects (mutations) that can cause family cancer syndromes and lead to them getting the 
disease. These syndromes often lead to cancer that occurs at a younger age than is usual. 
They are also linked to other cancers besides colorectal cancer. Some of these syndromes are 
also linked to polyps. Identifying families with these inherited syndromes is important 
because it lets doctors recommend specific steps, such as screening and other preventive 
measures when the person is younger. The most common inherited syndromes linked with 
colorectal cancers are familial adenomatous polyposis (FAP) and hereditary non-polyposis 
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colorectal cancer (HNPCC), but other rarer syndromes can also increase colorectal cancer 
risk. 
e) Familial adenomatous polyposis (FAP) (32) 
FAP is caused by changes (mutations) in the APC gene that a person inherits from his 
or her parents. About 1% of all colorectal cancers are due to FAP. The most common type of 
FAP causes people to develop hundreds or thousands of polyps in their colon and rectum, 
usually in their teens or early adulthood. Cancer usually develops in 1 or more of these 
polyps as early as age 20. By age 40, almost all people with this disorder will have developed 
colon cancer if the colon isn‟t removed first to prevent it. Polyps that can turn into cancer can 
also develop in the stomach and small intestine. 
f) Hereditary non-polyposis colon cancer (HNPCC) (33) 
HNPCC, also known as Lynch syndrome, accounts for about 2% to 4% of all 
colorectal cancers. In most cases, this disorder is caused by an inherited defect in either the 
gene MLH1 or the gene MSH2, but other genes can also cause HNPCC. The genes involved 
normally help repair DNA damage. The cancers in this syndrome also develop when people 
are relatively young, although not as young as in FAP. People with HNPCC may also have 
polyps, but they only have a few, not hundreds as in FAP. The lifetime risk of colorectal 
cancer in people with this condition may be as high as 80%. 
g) Turcotsyndrome (32) 
This is a rare inherited condition in which people are at increased risk of adenomatous 
polyps and colorectal cancer, as well as brain tumors. There are actually 2 types of Turcot 
syndrome: 
 One can be caused by gene changes similar to those seen in FAP, in which cases the 
brain tumors are medulloblastomas. 
 The other can also be caused by gene changes similar to those seen in HNPCC, in 
which cases the brain tumors are glioblastomas. 
h) Racial and ethnic background (32) 
African Americans have the highest colorectal cancer incidence and mortality rates of 
all racial groups in the United States. The reasons for this are not yet understood. Jews of 
Eastern European descent (Ashkenazi Jews) have one of the highest colorectal cancer risks of 
 
28 
any ethnic group in the world. Several gene mutations leading to an increased risk of 
colorectal cancer have been found in this group. The most common of these DNA changes, 
called the I1307K APC mutation, is present in about 6% of American Jews. 
i) Type 2 diabetes  (34) 
People with type 2 (usually non-insulin dependent) diabetes have an increased risk of 
developing colorectal cancer. Both type 2 diabetes and colorectal cancer share some of the 
same risk factors (such as excess weight). But even after taking these factors into account, 
people with type 2 diabetes still have an increased risk. They also tend to have a less 
favorable prognosis (outlook) after diagnosis. 
EPIDEMIOLOGY 
Colorectal cancers remain the third most common cancer and the third most common 
cause of cancer-related mortality in the US. The American Cancer Society estimates that 
93,090 individuals will be diagnosed with colon cancer in the United States in 2015. 
Combined estimates for colon and rectal cancer are for 49,700 deaths in 2015. Worldwide, 
colorectal cancer is the second most common in cancer in women (614,000 cases, 9.2% of all 
cancers) and the third most common in men (746,000 cases, 10.0% of the total). 
Geographically, the incidence varies as much as 10-fold. The highest estimated rates are in 
Australia/New Zealand (per 100,000 population, 44.8 in men and 32.2 in women), and the 
lowest in Western Africa (per 100,000 population, 4.5 in men and 3.8 in women). Mortality is 
lower (694,000 deaths, 8.5% of the total) with more deaths (52%) in the less developed 
regions of the world, reflecting a poorer survival in these regions. There is less variability in 
mortality rates worldwide (six-fold in men, four-fold in women), with the highest estimated 
mortality rates in both sexes in Central and Eastern Europe (20.3 per 100,000 for men, 11.7 
per 100,000 for women), and the lowest in Western Africa (3.5 and 3.0, respectively) 
Signs and symptoms of colorectal cancer (35) 
Colorectal cancer may cause one or more of the symptoms below. If you have any of 
the following you should see your doctor: 
 A change in bowel habits, such as diarrhea, constipation, or narrowing of the stool, 
that lasts for more than a few days 
 A feeling that you need to have a bowel movement that is not relieved by doing so 
 
29 
 Rectal bleeding 
 Blood in the stool which may make it look dark 
 Cramping or abdominal (belly) pain 
 Weakness and fatigue 
 Unintended weight loss 
Colorectal cancers can bleed. While sometimes the blood can be seen or cause the stool to 
become darker, often the stool looks normal. The blood loss can build up over time, though, 
and lead to low red blood cell counts (anemia). Sometimes the first sign of colorectal cancer 
is a blood test showing a low red blood cell count. Most of these problems are more often 
caused by conditions other than colorectal cancer, such as infection, hemorrhoids, irritable 
bowel syndrome, or inflammatory bowel disease. Still, if you have any of these problems, it's 
important to see your doctor right away so the cause can be found and treated, if needed. 
DIAGNOSIS (36) 
a) Medical history and physical exam. 
b) Blood tests 
a. Complete blood count (CBC) 
b. Liver enzymes  
c. Serum chemistries  
d. Renal function tests 
e. Tumor markers 
Colorectal cancer cells sometimes make substances called tumor markers that can be 
found in the bloodstream. The most common tumor markers for colorectal cancer are carcino 
embryonic antigen (CEA) and CA 19-9. 
In case of positive results of the physical exam or blood tests, colorectal cancer might be 
present, and can be confirmed by recommending more tests. This most often is colonoscopy, 
but sometimes other tests may be done first. 
 Colonoscopy 
 Chest x-ray 
 Biopsy 
 Gene test 
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 Microsatellite instability (MSI) testing 
 Imaging tests 
 Magnetic resonance imaging (MRI) scan 
 Computed tomography (CT or CAT) scan: General 
 
a) CT with portography: Checks veins and blood vessels 
b) CT-guided needle biopsy: Suspected area of cancer lies deep within the body. 
 Ultrasound 
a) Endorectal ultrasound 
b) Intraoperative ultrasound 
 Positron emission tomography (PET) scan 
 Angiography 
TREATMENT 
After the cancer is found and staged, your cancer care team will discuss your 
treatment options with you. The main types of treatment that can be used for colon and rectal 
cancer are: 
 Surgery for colon and rectal cancer Surgery is the only curative modality for localized 
colon cancer (stage I-III). Surgical resection potentially provides the only curative option 
for patients with limited metastatic disease in liver and/or lung (stage IV disease), but the 
proper use of elective colon resections in non-obstructed patients with stage IV disease is 
a source of continuing debate. 
 
 Radiation therapy although radiation therapy remains a standard modality for patients 
with rectal cancer, it has only a limited role in colon cancer. Radiation therapy is not used 
in the adjuvant setting, and in metastatic settings it is used only for palliative therapy in 
selected metastatic sites such as bone or brain metastases. Newer, more selective ways of 
administering radiation therapy, such as stereotactic radiotherapy and tomotherapy, are 
currently being investigated. In the future, these techniques may extend the indications for 
radiotherapy in the management of colon cancer. 
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 Chemotherapy (37-39) 5-Fluorouracil remains the backbone of chemotherapy regimens for 
colon cancer, both in the adjuvant and metastatic setting. In addition to 5-fluorouracil, 
oral fluoropyrimidines such as capecitabine (Xeloda) and tegafur are increasingly used as 
monotherapy or in combination with oxaliplatin (Eloxatin) levamisole and irinotecan 
(Camptosar) The standard chemotherapy for patients with stage III and some patients 
with stage II colon cancer for the last two decades consisted of 5-fluorouracil in 
combination with adjuncts such as levamisole and leucovorin. This approach has been 
tested in several large randomized trials and has been shown to reduce individual 5-year 
risk of cancer recurrence and death by about 30%.classification of drugs used in treatment 
of colorectal cancer. 
Commonly used combination regimens for adjuvant therapy include the following (40, 41) 
a) 5-Fluorouracil + leucovorin (weekly schedule, low-dose leucovorin)  
 5-Fluorouracil: 500 mg/m2 intravenous (IV) weekly for 6 weeks  
 Leucovorin: 20 mg/m2 IV weekly for 6 weeks, administered before 5-fluorouracil  
 Repeat cycle every 8 weeks for a total of 24 weeks  
b) 5-Fluorouracil + levamisole (weekly schedule, low-dose levamisole)  
 5-Fluorouracil : 450 mg/m2 intravenous (IV) weekly once for 6 weeks  
 Levamisolehydrochloride : 50 mg T.I.D. daily for 6 weeks,  
 Repeat cycle every 8 weeks for a total of 24 weeks  
c) Oxaliplatin + 5-fluorouracil + leucovorin (FOLFOX4)  
 Oxaliplatin: 85 mg/m2 IV on day 1 
 5-Fluorouracil: 400 mg/m2 IV bolus, followed by 600 mg/m2 IV continuous infusion 
for 22 hours on days 1 and 2  
 Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-
fluorouracil Repeat cycle every 2 weeks for a total of 12 cycles Commonly used 
combination regimens for metastatic disease include the following  
a) Irinotecan + 5-fluorouracil + leucovorin (FOLFIRI regimen)  
 Irinotecan: 180 mg/m2 IV on day 1 
 5-Fluorouracil: 400 mg/m2 IV bolus on day 1, followed by 2400 mg/m2 IV 
continuous infusion for 46 hours  
 Leucovorin: 400 mg/m2 IV on day 1 as a 2-hour infusion, prior to 5-fluorouracil  
 Repeat cycle every 2 weeks  
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b) Oxaliplatin + 5-fluorouracil + leucovorin (FOLFOX6)  
c) Oxaliplatin: 85-100 mg/m2 IV on day 1 
 5-Fluorouracil: 400 mg/m2 IV bolus on day 1, followed by 2400 mg/m2 IV 
continuous infusion for 46 hours  
 Leucovorin: 400 mg/m2 IV on day 1 as a 2-hour infusion, before 5-fluorouracil  
 Repeat cycle every 2 weeks c) Capecitabine + oxaliplatin (XELOX)  
 Capecitabine: 850-1000 mg/m2 PO bid on days 1-14  
 Oxaliplatin: 100-130 mg/m2 IV on day 1  
 Repeat cycle every 21 days d) FOLFOX4 + bevacizumab 
 Oxaliplatin: 85 mg/m2 IV on day 1 
 5-Fluorouracil: 400 mg/m2 IV bolus, followed by 600 mg/m2 IV continuous 
infusion on days 1 and 2  
 Leucovorin: 200 mg/m2 IV on days 1 and 2 as a 2-hour infusion before 5-
fluorouracil  Bevacizumab: 10 mg/kg IV every 2 weeks  
 Repeat cycle every 2 weeks 
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LITRATURE REVIEW 
1. AnuranjitaKundu et al., (2012) (42), This study reveals that oral controlled release of 
Norfloxacin can be successfully achieved by ionotropic gelation technique using sodium 
alginate as polymer. Prepared microbeads shown higher drug entrapment efficiency and 
prolonged release characteristics. Norfloxacin release from micro beads was influenced 
by different alginate concentrations. Among the different formulations of micro beads, 
A3 was estimated as best formulation because this formulation drug release was observed 
that drug was released in controlled manner. 
 
2. M. S. Shetage et al., (2015) (43), The present study is an attempt to minimize the dosing 
frequency and to target the Metoprolol succinate to the colon. Drug loaded pellets are 
coated with pH independent Eudragit RS100 and further coated with pH dependent 
Eudragit S100 in R and D pan coater. 32 full factorial design is applied to study the effect 
of extent of Eudragit S100 coating %w/w (X1) and extent of Eudragit RS100 coating 
%w/w (X2) as independent variables on the dependent variables (responses) are Y1=Q5 
(% released after lag time of 5h) and Y2=Q90 (90% of drug release within 12h). The 
formulation were further characterized by in vitro dissolution study, drug release kinetics 
and micromeritic properties. 32 factorial designs reveals that coating level of both the 
coats play a significant role in drug release property of which coating level of Eudragit 
RS 100 was more significant after the tablet reaches colon. Design expert software gives 
D5 as optimized batch having 20% w/w Eudragit RS 100 and 30% w/w with S100 as the 
drug release was below 20% in SIF so that it can be efficiently colon targeted, and the 
release is sustained up to 12 hr which is desirable for twice daily dosing of metoprolol. 
 
3. Anuradha Mishra et al., (2008) (44), performed the Modification of Okra mucilage with 
acrylamide: Synthesis, characterization and swelling behavior. In the present 
communication, the synthesis and characterization of Okra mucilage, a food grade and 
water-soluble polysaccharide, based-materials are described. Okra mucilage has been 
modified by grafting acrylamide (AAm) for developing the new green polymeric 
materials of specialty applications. Grafting has been done under N2atmosphere using 
redox initiator and hydrogels were prepared by using N,N-methylenebisacrylamide (NN-
MBAAm) as cross linker. The effect of monomer concentration, initiator concentration, 
reaction time and temperature in terms of grafting efficiency (%GE), percent grafting 
(PG) and percent gel (%G) has been investigated. The grafted polymers and hydrogels 
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were characterized by SEM, XRD and FTIR techniques to study various structural 
aspects. The swelling behavior of the cross-linked polymeric material has also been 
studied as a function of time, temperature and pH. The application area of these polymers 
is varied from biomaterials to the wastewater treatment. 
 
4. S.K. Bajpai et al., (2004) (45), Investigated the swelling/degradation behaviour of alginate 
beads cross-linked with Ca2+ and Ba2+ ions. Spherical beads have been prepared by 
ionotropic gelation of sodium alginate in the presence of CaCl2 and BaCl2 solutions and 
their swelling behavior has been studied. The barium ion-cross-linked beads exhibit 
almost minimum swelling of 40% in PBS at pH 7.4 but possess greater stability while 
calcium alginate beads exhibit nearly 160% of water uptake and subsequently dissolve. 
The beads appear to swell through ion-exchange process which was confirmed by 
monitoring the Ca2+ release from the calcium alginate beads. The release was found to be 
diffusion controlled. On treatment with 0.1 M HCl, the calcium alginate beads 
demonstrated a decrease in water uptake in PBS at pH 7.4 with faster degradation while 
for acid treated barium alginate beads, the water uptake was found to increase on 
treatment with HCl. When the two beads samples were put in media of continuous 
varying pH (to mimic the passage of beads from mouth to colon), barium alginate beads 
possessed greater stability, thus showing potential to be used for colon targeted oral 
delivery. 
 
5. UzmaFarooq et al., (2013) (46), This study deals with extraction and characterization of 
okra (Abelmoschus esculentus) mucilage as pharmaceutical excipients. Using water based 
extraction method, the yield of mucilage was found to be 11.44%. Characterization of the 
extracted mucilage was done by various parameters such as micromeritic studies, flow 
behaviour, organoleptic properties, surface tension, and viscosity, loss on drying, ash 
value and swelling index. The result showed that extracted okra mucilage exhibited good 
flow properties (Angle of repose 27.29°), the surface tension of 0.25% w/v solutions of 
mucilage was found to be 0.0405 joule/m2, total ash was 7.53% w/w, loss on drying was 
9.917% and pH was found to be 7.5. Extracted mucilage was soluble in warm water while 
insoluble in organic solvents. This showed that this can be safely used in dosage form 
without causing any adverse effect. 
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6. MohdSuffianYusoff et al., (2014) (47), have prepared and characterized alginate beads by 
drop weight. The preparation and characterization of macro alginate beads are always 
associated with appropriate techniques involving precise measurement of shape, size, 
volume and density of the products. Depending on the type of application, encapsulation 
of macro alginate beads can be accomplished by various techniques including chemical, 
ionotropic, physical and mechanical methods. This work describes a method for preparing 
macro alginate beads through drop weight. The macro beads (2.85–3.85 mm) were 
prepared via different concentrations of alginate (0.5, 1.0, 1.5 and 2.0 g/L), dripping tip 
size (0.04–0.14 cm) and immersion into a predetermined concentration of calcium 
chloride (CaCl2) bath. A custom made dripping vessel fabricated from acrylic plastic, 
connected to an adjustable dripping clamp was used to simulate the dripping process of 
the molten alginate at different tip sizes. It was observed that at different dripping tips, the 
correction factor for the alginate slurry was found in the range of 0.73–0.83. Meanwhile, 
the lost factor, KLF was observed at 0.93–2.3 and the shrinkage factors were limited to 
2.00% from the overall distributed data. It was concluded that liquid properties had no 
effect on the liquid lost factor. The bead size prediction for different concentrations of 
alginate solution was compared to the experimental data. Subsequently, it was concluded 
that increasing the tip size caused the bead size to deviate almost 20% when compared to 
the experimental and predicted values, respectively. 
 
7. Ameena K et al., (2010) (48), Isolated the mucilages from Hibiscus rosasinensis linn. and 
Okra (Abelmoschus esculentus linn.) and studied of the binding effects of the mucilage. 
To isolate and evaluate comparatively the binding efficacy of the mucilages obtained 
from the plants of Hibiscus rosasinensis and Okra (Abelmoschus esculentus). Methods: 
Extraction of mucilages from the leaves of Hibiscus and pods of Okra (Ladies finger) was 
carried out by a cold maceration process. The extracted mucilages were subjected to 
various physicochemical properties for its suitability as an excipient in the formulation of 
tablet dosage form. Different concentrations (10, 8, 5, 2 and 1% w/v) of binder solutions 
of Hibiscus and Okra were used for the formulation of tablets and the formulated tablets 
were evaluated by studying the standard parameters like diameter, thickness, weight 
variation, hardness, friability, disintegration and in vitro dissolution. Stability studies of 
the formulated tablets were conducted for four weeks. Results: The formulated tablets 
prepared using the mucilages of both Hibiscus and Okra had good appearance. The in 
vitro drug release profile of the tablets prepared using Okra mucilage had an optimum of 
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90% at a mucilage concentration of 1% w/v concentration mucilage itself within 4 h. 
Conclusions: According to the observations, the lower concentration levels of Okra can 
be used as an alternative binder to starch. The higher concentration levels of Okra 
mucilage show a slow and sustained release, and can be considered as an alternative 
natural excipient in the modified drug delivery systems. At the same time, the above 
natural excipient of Hibiscus mucilage could be used as a platform for prolonged release 
if its binder concentrations are increased 
 
8. Anbarasan B et al., (2015) (49), development of formulation and in-vitro evaluation of  
capecitabine loaded Fe3O4 nanoparticles modified with plga-peg polymer for colon cancer 
treatment. This present study was to investigate the synthesis of Fe3O4 nanoparticles by 
chemical precipitation method. The Fe3O4 nanoparticles were coated with the polymers 
PLGA,PEGand loaded with the drug capecitabine for the targeting of colon cancer which 
will be distributed in the large intestine by applying, the external magneticfield. It gets 
localized in the area of colon cancer cells. After the applied external magnetic field, the 
ironoxides (Fe3O4 nanoparticles) get heated to 37ºC - 40ºCand the tumour cell gets 
destroyed. The Fe3O4nanoparticles were also called as super para magnetic Iron oxide 
nanoparticles. They were very smart materials and mostly used for the applications in 
medicine like targeted drug delivery system, diagnostic cancer imaging and their 
therapeutic applications. 
 
9. M. S. Khan et al., (2010) (50), Developed and Evaluated pH -Dependent Micro Beads for 
Colon Targeting. The purpose of this research was to develop and evaluate 
multiparticulate of alginate and chitosan hydrogel beads exploiting pH sensitive property 
for colon-targeted delivery of theophylline. Alginate and chitosan beads were prepared by 
ionotropic gelation method followed by enteric coating with Eudragit S100. All 
formulations were evaluated for particle size, encapsulation efficiency, swellability and in 
vitro drug release. In vitro dissolution studies performed following pH progression 
method demonstrated that the drug release from coated beads depends on coat weights 
applied and pH of dissolution media. Mechanism of drug release was found to be 
swelling and erosion-dependent. The studies showed that formulated alginate and 
chitosan beads can be used effectively for the delivery of drug to colon and a coat weight 
of 20% weight gain was sufficient to impart an excellent gastro resistant property to the 
beads for effective release of drug at higher pH values. 
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10. Bagyalakshmi et al., (2011) (51), formulated physical characterization and in-vitro release 
studies of prednisolone alginate beads for colon targeting by ionotropic gelation. This 
article shall give an overview on drug delivery systems for new therapeutic strategies in 
the treatment of inflammatory bowel disease. Conventional drug delivery systems are 
tightly adapted from developments of colonic delivery by oral administration triggered by 
release mechanism owing to the physiological environment that these systems encounter 
in the colonic region. The newer developments in this context aim for an increased 
selectivity of drug delivery by targeting mechanisms which have a closer relation to patho 
physiological particularities of the disease. The objective of the present study was to 
microencapsulate the anti-inflammatory drug (prednisolone) to provide controlled release 
and colon targeting. Alginate beads of prednisolone were formulated by ionotropic 
gelation and further coated with Eudragit S-100 and the variables studied includes 
concentration of sodium alginate, different cross linking agents were evaluated with 
respect to particle size, surface characteristics entrapment efficiency and in vitro release 
behavior. IR spectroscopic study confirmed the absence of any drug interaction. DSC 
analysis revealed that the drug was uniformly dispersed in the alginate beads. The mean 
particle size increases with increasing the polymer concentration. The shape of alginate 
beads has acceptable sphericity and surfaces were rough which were confirmed by SEM 
photograph. The entrapment efficiency in different formulation varied from 69% to 81%. 
The in vitro release profiles were also altered significantly by changing various 
parameters. The kinetic modeling of the release data indicates that prednisolone released 
from alginate beads followed by Korsemeyer‟s model. The above observations suggest 
that prednisolone can be developed as colon targeting drug delivery system with sodium 
alginate 2.5% using Calcium chloride as cross linking agent and coated with Eudragit S-
100. 
 
11. Md. Hassan Kawsar et al., (2011) (52), Developed and Evaluated of Diclofenac Sodium 
Loaded Alginate Cross-Linking Beads. Sustained-release polymeric beads containing 
Diclofenac sodium fabricated with sodium alginate were prepared by the ionotropic 
gelation method. Drugs were blended with sodium alginate in 1:1, 1:2, 1:2.5, 1:3, 1:3.5 
and 2:2 ratios. Here, calcium chloride and aluminium sulphate was used as a cross-linking 
agent. Beads of Diclofenac sodium were prepared with different concentrations of drug, 
polymers and electrolytes. Prepared beads were evaluated for their drug entrapment 
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efficiency, loss on drying, swelling index and release behavior. The entrapment efficiency 
of drug in beads depended on the amount of drug and polymer ratio as well as electrolyte 
concentration. The percent entrapment was highest when beads were prepared with 5 % 
electrolyte solution. In case of calcium chloride solution with highest amount of polymer 
i.e.3.5 gram the entrapment efficiency was 75.12 %. But, in aluminium sulphate solution 
the entrapment efficiency was highest (99.06 %) when polymer amount was 2 gram. In 
most cases, the swelling study revealed that, up to third hour the formulations swelled 
high, but swelling started to decrease after fourth hour. In case of loss on drying of beads 
after formation showed that, the rate of solvent loss until three hours eventually continued 
to increasing but then decreased. Invitro dissolution data showed that, with increasing 
drug, polymer and electrolyte amount the Diclofenac release percentage also decreased. 
Among the sixteen formulations, nine of them followed Higuchi release kinetics. Thus, 
by modifying the polymer amount and the selection of cross linking agent plays a vital 
role in efficiency and sustained-release characteristics. 
 
12. EhsanTaghizadehDavoudi et al., (2013) (53), Prepared and Characterized Gastric 
Floating Dosage Form of Capecitabine Gastrointestinal disturbances, such as nausea and 
vomiting, are considered amongst the main adverse effects associated with oral anticancer 
drugs due to their fast release in the gastrointestinal tract (GIT). Sustained release 
formulations with proper release profiles can overcome some side effects of conventional 
formulations. The current study was designed to prepare sustained release tablets of 
Capecitabine, which is approved by the Food and Drug Administration (FDA) for the 
treatment of advanced breast cancer, using hydroxypropyl methylcellulose (HPMC), 
carbomer 934P, sodium alginate, and sodium bicarbonate. Tablets were prepared using 
the wet granulation method and characterized such that floating lag time, total floating 
time, hardness, friability, drug content, weight uniformity, and in vitro drug release were 
investigated. The sustained release tablets showed good hardness and passed the friability 
test. The tablets floating lag time was determined to be 30–200 seconds, and it floated 
more than 24 hours and released the drug for 24 hours. Then, the stability test was done 
and compared with the initial samples. In conclusion, by adjusting the right ratios of the 
excipients including release-retarding gel-forming polymers like HPMC K4M, Na 
alginate, carbomer934P, and sodium bicarbonate, sustained release Capecitabine floating 
tablet was formulated.  
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13. Suchitra.Domala et al., (2013) (54), Formulation And Evaluation Of Sustained Release 
Tablets Of Capecitabine Using Different Hydrophylic Polymers. The objective of this 
work was to formulate and evaluate the sustained release matrix tablets of Capecitabine - 
an anti-cancer drug used in the treatment of metastatic breast cancer and colorectal 
cancers by using various hydrophilic polymers such as Xanthan gum, Carbopol and 
hydroxy propyl methyl cellulose K 100 [HPMC K 100] as cost-effective, nontoxic, easily 
available, with suitable hydrophilic matrix systems. Matrix tablets of Capecitabine were 
prepared by wet granulation method. Granules were evaluated for pre compression 
parameters such as bulk density, tapped density were found within limits. Angle of repose 
showed that the blend was freely flowing and Carr‟s index was in 11.29 ± 0.324 to 14.53 
± 0.926 showing that the powered blend were having good compressibility. The prepared 
tablets were evaluated for various post compression parameters such as hardness, 
friability, uniformity of weight were showed good physical properties by satisfying with 
the limits. The uniformity of drug content was found to be 99.63 ± 0.65% to 99.08 ± 
0.28% indicating that the drug content was uniform in all batches. The dissolution test 
was performed in the phosphate buffer media (pH 6.8) up to 24 hours. Among the 
different formulations prepared, formulation no. 2 with HPMC K 100 10%, Xanthan gum 
10% has the % drug release 98.44% up to 24 hours was found to be satisfactory compare 
to other formulations. Overall, the safety and patient compliance was improved as well as 
the efficacy of the drug; this was achieved by reducing the frequency of drug 
administration and better control of drug plasma levels. 
 
14. S. Latha et al., (2012) (55), formulated and evaluated capecitabine nanoparticles for 
cancer therapy. The main objective of this study is to formulate the Capecitabine loaded 
nanoparticles of chitosan (CS) cross-linked with Tripolyphosphate (TPP) for anti-cancer 
therapy, in order to enhance bioavailability and to reduce dose frequency. Formulation of 
capecitabine loaded CS/TPP nanoparticles solution was prepared by dissolving chitosan 
(CS) in 1% (w/v) acetic acid solution under stirring at room temperature. The CS solution 
was diluted with deionized water to produce different concentration. CS/TPP 
nanoparticles were prepared according to the ionotropic gelation process. For preparation 
of Capecitabine loaded CS/TPP nanoparticles, the capecitabine solution with various 
concentrations was added slowly to CS solution and TPP solution was added drop wise to 
the mixture with mild stirring for 60 min. The prepared nanoparticles were characterized 
by FT-IR spectroscopy to confirm the cross linking reaction between CS and cross 
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linking agent. X-ray diffraction was performed to reveal the crystalline nature of the drug 
after encapsulation. Capecitabine were loaded into the nanoparticles and the average size 
was found to be in the range of 120-250 nm. The Polydispersity index of the 
nanoparticles was found to be 0.200-0.400. The nanoparticles formed were spherical in 
shape with high zeta potentials (higher than +20 to +32). In vitro release studies in 
phosphate buffer saline (pH 7.4) showed an initial burst effect and followed by a slow 
drug release. The drug release followed zero order kinetics and a Fickian transport 
mechanism. From all these results it is concluded that the six formulations are 
recommended for future studies like Nano dry powder preparation. Drug loading capacity 
was determined by UV spectrophotometer at 240nm. The formulation was optimized for 
their particle size, drug release and entrapment efficiency for three independent variables 
by Box-Bekhen design. 
 
15. Melina Arnold et al., (2016) (56), Global patterns and trends in colorectal cancer 
incidence and mortality. The global burden of colorectal cancer (CRC) is expected to 
increase by 60% to more than 2.2 million new cases and 1.1 million deaths by 2030. In 
this study, we aim to describe the recent CRC incidence and mortality patterns and trends 
linking the findings to the prospects of reducing the burden through cancer prevention 
and care. 
 
16. R. Ndjouenkeu et al., (2011) (57)Rheology of okra (Hibiscus esculentus L.) and dika nut 
(Irvingiagabonensis) polysaccharides. Polysaccharide extracts were prepared from two 
traditional food thickeners with extensive domestic use in central and western parts of 
Africa: okra (Hibiscus esculentis L.) and the seed kernel from „dika nut‟ 
(Irvingiagabonensis). Both demonstrated typical polyelectrolyte behaviour in solution, 
and were therefore studied under fixed ionic conditions (0.1 M NaCl), yielding intrinsic 
viscosities of [η] = 7.6 dl g−1 for okra and [η] = 4.4 dl g−1 for dika. Concentrated 
solutions gave mechanical spectra typical of entangled networks, with close Cox-Merz 
superposition of η(ω) and η(Ȗ). The variation of „zero-shear‟ specific viscosity with 
degree of space-occupancy (c[η]) was also broadly similar to the general form observed 
for most disordered polysaccharides, but with greater separation of c∗ and c∗∗ and steeper 
slope of log ηsp vs. log c above c∗ (~4.0 for okra and ~4.6 for dika, in comparison with 
the usual value of ~3.3). As found for normal disordered polysaccharides, the shear-
thinning behaviour of dika gum could be reduced to a single „master-curve‟ for all 
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concentrations above c∗∗, but the absolute value of the terminal slope of log (η-ηs) vs. log ⋗g was unusually low (~0.58, in comparison with the normal value of ~0.76). Terminal 
slopes for okra gum were also unusually low, and varied systematically with polymer 
concentration. These departures from normal solution properties are tentatively ascribed 
to compact macromolecular structures, coupled, in the case of okra gum, with a strong 
tendency to self-association. 
 
17. C.Radhika et al., (2015) (58), Formulated and In-Vitro Evaluated Of Microspheres 
Embedded With Capecitabine. Recent drug discovery using advanced techniques such as 
genomics, combinatorial chemistry, high throughput screening and in silico three 
dimensional drug design has yielded drug candidates with low water solubility and thus 
an inherently low mucosal permeability which makes the development of pharmaceutical 
formulations difficult. To overcome these, particulate systems like micro particles have 
been used as a physical approach to alter and improve the pharmacokinetic and 
pharmacodynamics properties of various types of drug molecules. They have been used in 
vivo to protect the drug entity in the systemic circulation, restrict access of the drug to the 
chosen sites and to deliver the drug at a controlled and sustained rate to the site of action. 
Various polymers have been used in the formulation of micro particles for drug delivery 
research to increase therapeutic benefit, while minimizing side effects. The review 
embraces various aspects of micro particle formulations, characterization, effect of their 
characteristics and their applications in delivery of drug molecules and therapeutic genes. 
 
18. UbaidullaUdhumansha et al., (2007) (59), Developed and characterized chitosan 
succinate microspheres for the improved oral bioavailability of insulin. The present study 
describes the fabrication of insulin loaded chitosan succinate microspheres to improve the 
efficacy of orally administered insulin. Chitosan succinate polymer was synthesized and 
its microspheres were prepared by emulsion phase separation technique. The 
microspheres were characterized by FT-IR spectroscopy, scanning electron microscopy, 
particle size, X-ray diffraction, and swelling index. Insulin was loaded into the 
microspheres by passive absorption technique. The ability of microspheres to protect 
insulin from gastric enzymatic degradation was investigated. Stability of insulin in the 
microspheres was determined by gel electrophoresis and circular dichroism (CD). In vitro 
release studies were performed under simulated gastric and intestinal pH conditions (pH 
2.0 and pH 7.4). The pharmacokinetic parameters were monitored after oral 
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administration of insulin loaded chitosan succinate microspheres, chitosan succinate–
insulin solution, as well as after subcutaneous injection of insulin to diabetic rats. The 
degree of succinate substitution in the synthesized polymer was 16%. The prepared 
microspheres were spherical with an average diameter of 49 mm. The insulin-loading 
capacity was 62%. Chitosan succinate microspheres were found to protect the degradation 
of insulin from gastric enzymes. The encapsulated insulin was quickly released in 
simulated intestinal fluid (SIF, pH 7.4), whereas a small fraction of insulin was released 
in simulated gastric fluid (pH 2.0). The relative pharmacological efficacy for chitosan 
succinate microspheres (16%) was almost fourfold higher than the efficacy of the 
chitosan succinate–insulin solution administration (4%). The results suggest that chitosan 
succinate microspheres could be used as a potential carrier for oral insulin delivery.  
 
19. MerveOlukman et al., (2012) (60), Release of Anticancer Drug 5-Fluorouracil from 
Different Ionically cross-linked Alginate Beads. In this research, the release of 5-
Fluorouracil (5-FU) from different ionically cross-linked alginate (Alg) beads was 
investigated by using Fe3+, Al3+, Zn2+ and Ca2+ ions as crosslinking agent. The prepared 
beads were characterized by Fourier Transform Infrared Spectroscopy (FTIR) Differential 
Scanning Calorimetry (DSC) and Scanning Electron Microscopy (SEM). The drug 
release studies were carried out at three pH values 1.2, 6.8 and 7.4 respectively each for 
two hours. The effects of the preparation conditions as cross linker type, drug/polymer 
(w/w) ratio, cross linker concentration and time of exposure to cross-linked on the release 
of 5-FU were investigated for 6 hours at 37˚C. It was observed that 5-FU release from the 
beads followed the order of Fe > Zn > Al > Ca-Alg and increased with increasing 
drug/polymer ratio. At the end of 6 hours, the highest 5-FU release was found to be 90% 
(w/w) for Fe-Alg beads at the drug/polymer ratio of 1/8 (w/w), cross linker concentration 
of 0.05 M, exposure time of 10 minutes respectively. The swelling measurements of the 
beads supported the release results. Release kinetics was described by Fickian and non-
Fickian approaches.  
 
20. Priyanka Sinha et al., (2015) (61), Zinc (Zn2+)-ion induced diclofenac sodium (DS)-
loaded alginate-okra (Hibiscus esculentus) gum (OG) blend beads was successfully 
formulated through Zn2+-ion induced ionic-gelation cross-linking method in a complete 
aqueous environment. Effects of polymer-blend ratio and cross-linker concentration on 
drug encapsulation efficiency (DEE) and cumulative drug release at 8 h (R8h) were 
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optimized by 32-factorialdesign. The optimized formulation of Zn2+-ion induced DS-
loaded alginate-OG beads demonstrated 89.27 ± 3.58% of DEE and 43.73 ± 2.83% of 
R8h. The bead sizes were within 1.10 ± 0.07 to 1.38 ± 0.14 mm. The bead surface 
morphology was analyzed by SEM. The drug–polymer interaction in the optimized bead 
matrix was analyzed by FTIR and P-XRD. These beads exhibited sustained in vitro drug 
release over a prolonged period of 8 h and followed controlled-release (zero-order) 
pattern with super case-II trans-port mechanism. The swelling and degradation of the 
optimized beads was influenced by the pH of test mediums, which might be suitable for 
intestinal drug delivery. 
21. G. Pavani et al., (2013) (62), Formulated And Evaluated Of Capecitabine Sustained 
Release Tablets. The objective of the present investigation was to formulate and 
devaluate sustained release of Capecitabine tablets. Capecitabine sustained release tablets 
were developed different polymers HPMC K 100, Carbopol 974 and Xanthan Gum with 
different ratios. Totally 9 formulations were prepared. Sustained release tablets of 
Capecitabine were prepared by wet granulation technique. The prepared granules 
evaluated in terms of their Pre-compression studies like Tapped Density, Bulk Density, 
Angle of repose, Carr‟s Index and Hausner‟s ratio. The tablets were evaluated by Post-
compression studies like hardness, thickness, friability and in vitro studies. The results of 
in vitro drug release studies showed that formulation-2 (API and HPMC and Xantham 
gum) has better drug release (98.44%) for 24hrs.  
 
22. Divyen Shah et al., (2011) (63), designed a study to investigate the combined influence of 
three independent variables on two dependent variables for the preparation of 
nanoparticles of levamisole hydrochloride. The nanoparticles were prepared by ionotropic 
gelation method. The three independent variables are the chitosan/sodium 
tripolyphosphate ratio, pH of sodium tripolyphosphate and levamisole concentration; 
while particle size and percentage drug entrapment were dependent variables. The 
nanoparticles were prepared by using 23 factorial design to obtain high entrapment 
efficiency and small size. The polynomial equation can be used to predict the responses. 
The prepared nanoparticles show busted release for the first 2 h and then show sustained 
release. The differential scanning calorimetry graphs indicate that drug is completely 
entrapped in nanoparticles and transmission electron microscopy images show that 
nanoparticles are spherical in shape and dense solid in nature. The mathematical model 
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obtained by 23 factorial design shows good relationship between independent variables 
and dependent variables for prediction. 
 
23. HarpreetKaur et al., (2013) (64), investigated colonic delivery using shellac as coat over 
the hard gelatin capsule. The drug delivery system was based on the gastrointestinal 
transit time concept, assuming colon arrival time to be 6 h. Rapidly disintegrating 
capsules containing 50mg 5-FU were coated with different concentration of shellac by 
dipping method. In order to find the suitable formulation, various formulation factors 
were investigated through series of in-vitro dissolution studies in buffer solution at pH 1.2 
for first 2 h, and at pH 6.8 for remaining hour. The results indicated that C4 is the most 
suitable formula in the approach of time dependent oral delivery system for colon 
targeting for achieving minimum release in the first five hours and maximum at the 24 th 
hour. The formulation C4 was then studied with different probiotics. Gp1 shows a release 
of 12.14 % in first five hours but, on 24 hours Gp1 shows a maximum release of 98.75 %. 
So the capsule with probiotc was found to be more effective than without probiotics. 
 
24. KuntalGanguly et al., (2011) (65), formulated 5-Flurouracil spherical microspheres by 
loading different concentrations of 5-Flurouracil (10, 20, and 30 %w/w) into polyethylene 
glycol cross-linked chitosan microspheres by using emulsion cross linking technique and 
then enteric coated it with cellulose acetate phthalate to facilitate drug targeting to the 
colon. The microspheres were evaluated for swelling index, encapsulation efficacy and 
in-vitro release characterization in simulated gastrointestinal tract conditions. The 
uncoated released 46-77% in acidic pH and 93-97% in alkaline pH whereas the CAP 
coated microspheres released 8-17% in acidic pH and 88-97% in alkaline pH. The study 
concluded that chitosan microspheres cross linked with PED and coated with CAP 
showed better colon targeting activity as they demonstrated better prolonged release for 
6-12 hrs by protecting from acidic environment of stomach. Kinetic studies showed that 
the release of drug is by super case II transport mechanism. 
 
25. Ramana G et al,. (2011) (66), prepared and characterized pectin alginate microspheres 
loaded with 5-Flurouracil and coated with ethyl cellulose for colon targeting. The 
microspheres were prepared by ionotropic gelation method and coated with ethyl 
cellulose. The various characterization parameters evaluated were drug-
excipientcompatability, drug entrapment effeciency, swellability, surface morphology, 
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invitro release studies and stability studies. DSC showed no interaction between the drug 
and excipients and hence was used in the formulation. Optimized formulation showed 
69.94% drug entrapment. The in-vitro release studies were carried out in the presence and 
absence of pectinase enzyme and found that the drug release was 93.25% and 97.82% 
respectively. The stability studies showed that there was no degradation of the 
formulation. Hence the experimental results demonstrated that ethyl cellulose-coated 
pectin microspheres have the potential to be used as a drug carrier for an effective colon-
targeted delivery system. 
 
26. Sridar et al., (2010) (67), developed and evaluated Multiparticulates of alginate and 
chitosan hydrogel beads exploiting pH sensitive property for colon-targeted delivery of 
theophylline. Alginate and chitosan beads were prepared by ionotropic gelation method 
followed by enteric coating with Eudragit S100. All formulations were evaluated for 
particle size, encapsulation efficiency, swellability and in vitro drug release. In vitro 
dissolution studies performed following pH progression method demonstrated that the 
drug release from coated beads depends on coat weights applied and pH of dissolution 
media. Mechanism of drug release was found to be swelling and erosion-dependent. 
Coated chitosan beads released more than 70% and coated alginate beads released more 
than 80% of drug in pH more than 7.0 while in acidic pH chitosan and alginate beads 
released 8% and 6 % respectively with a coat weigh of 20%. The studies showed that 
formulated alginate and chitosan beads can be used effectively for the delivery of drug to 
colon and a coat weight of 20% weight gain was sufficient to impart an excellent gastro 
resistant property to the beads for effective release of drug at higher pH values. 
 
27. Bose A et al., (2007) (68), prepared 5-flurouracil pellets coated with pectin and ethyl 
cellulose for the treatment of colon cancer. They studied pharmacodynamic and 
pharmacokinetic profiles of intracapsular coated pellets invivo in rats with reference to 
their to their site specific drug release outcomes. The pellets were prepared by extrusion 
spheronozation technique. In-vitro drug release, drug content, invivo pharmacokinetics, 
local colonic drug content, systemic haematology and clinical chemistry profiles of 
coated and uncoated pellets were examined against unprocessed drug. Invivo coated 
pellets reduced drug bioavailability and enhanced the drug acculmulation in the colon 
(179.13 μg of 5-FU/g rat colon content vs 4.66 μg of 5-FU/g rat colon content of 
conventional in-vivo film coated pellets at dose of 15mg/kg dose). The coated pellets 
 
46 
showed reduction in tumor size and number by reforming tubular epithelium with 
epithelium membrane and restricting expression of cancer from adenoma to 
adenocarcinoma. The coated pellets eliminated aberrant crypt foci which represented a 
pulsatile preneoplastic lesion in colon cancer. They did not implicit additional systemic 
toxicity. 
 
28. NandgudeTanajiDilip et al., (2016) (69), Formulated and Developed Colon Specific 
Multiparticulate System of Capecitabine. In the present study, the main objective was to 
develop a multiparticulate system containing chitosan microspheres for colon-specific 
drug delivery of capecitabine for the treatment of colorectal cancer. Materials and 
Methods: This study was based on the microbial degradability of chitosan microspheres. 
The microspheres were prepared with chitosan by emulsion cross linking method. A 
factorial design was applied to optimize the formulation. The effect of concentration of 
chitosan and drug: Polymer ratio was studied on particle size, % entrapment efficiency, 
and % drug release using 32 factorial designs. Results and Discussion: The prepared 
microspheres also analyzed for percentage yield, flow properties, and surface 
morphology. The results of analysis of variance test for responses measured indicated that 
the test is statistically significant. Conclusion: In vitro drug release studies were 
performed in a pH progression medium mimicking the conditions of the gastrointestinal 
tract showed a fast drug release initially demanded microencapsulation. 
 
29. EhsanTaghizadehDavoudi et al., (2013) (70), Preparation and Characterization of a 
Gastric Floating Dosage Form of Capecitabine. Gastrointestinal disturbances, such as 
nausea and vomiting, are considered amongst the main adverse effects associated with 
oral anticancer drugs due to their fast release in the gastrointestinal tract (GIT). Sustained 
release formulations with proper release profiles can overcome some side effects of 
conventional formulations. The current study was designed to prepare sustained release 
tablets of Capecitabine, which is approved by the Food and Drug Administration (FDA) 
for the treatment of advanced breast cancer, using hydroxypropyl methylcellulose 
(HPMC), carbomer934P, sodium alginate, and sodium bicarbonate. Tablets were 
prepared using the wet granulation method and characterized such that floating lag time, 
total floating time, hardness, friability, drug content, weight uniformity, and in vitro drug 
release were investigated. The sustained release tablets showed good hardness and passed 
the friability test. The tablets‟ floating lag time was determined to be 30–200 seconds, and 
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it floated more than 24 hours and released the drug for 24 hours. Then, the stability test 
was done and compared with the initial samples. In conclusion, by adjusting the right 
ratios of the excipients including release-retarding gel-forming polymers like HPMC 
K4M, Na alginate, carbomer934P, and sodium bicarbonate, sustained release 
Capecitabine floating tablet was formulated. 
 
30. PayamKhazaeli et al., (2013) (71), Formulated Ibuprofen Beads by Ionotropic Gelation. 
Microencapsulation has become a common technique in the production of controlled 
release dosage forms. Many results have been reported, concerning the use of alginate 
beads as controlled release drug formulations. Alginate has a unique gel-forming property 
in the presence of multivalent cations, in an aqueous medium. Ibuprofen is an excellent 
analgesic and antipyretic, non-steroidal anti-inflammatory agent with a high therapeutic 
index. Formulation of ibuprofen in beads could reduce its gastric ulcerogenicity. Hence, 
in this study the formation of Ca-alginate ibuprofen beads, through ionotropic gelation 
has been investigated. For this purpose, different cross- linking agents including: Ca2+, 
Ba2+, Mn2+, Co2+, Sn2+ and Pb2+, were used for bead preparation . Next, characterization 
of the beads, size distribution, and encapsulation efficiency of ibuprofen within the beads, 
the bead swelling and the drug release kinetic were investigated. Results showed that only 
Ca ion is suitable for the formation of ibuprofen beads. A good swelling profile for beads 
in phosphate buffer (pH=7.4) and the lack of swelling in hydrochloric acid (pH= 1.2), 
show the suitable nature of the beads. In addition, formulation of Na-alginate (2%) and 
Ca-chloride (2%) beadsresulted in an encapsulation efficacy of around 90%. The drug 
release studies showed a rapid and complete ibuprofen release from the beads, especially 
those prepared from Na-alginate (2%) and Ca-chloride (2%), in phosphate buffer 
medium. However, no detectable drug release was observed within the acidic medium.In 
conclusion, ibuprofen is capable of being n be microencapsulated as a bead 
formulation,with suitable properties and release profile.  
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AIM AND OBJECTIVE 
Alginates are generally regarded as safe (GRAS) by the FDA .Sodium alginate (SA) 
is the sodium salt of alginic acid, which is aco-polymer of ȕ-d-mannuronic acid (M) and ∞-l-
guluronic acid(G) having 1,4-glycosidic linkage between them. It has been used in various 
pharmaceutical applications. It produces cured gel matrices in the presence of multivalent 
cations like Ca2+, Cd2+,Ba2+, Zn2+, Al3+, etc., due to intermolecular ionic-gelation cross-
linking between COO−groups located on the SA backbone and these metal cations. Utilizing 
this property of SA, various alginate gel beads were prepared for the delivery of various 
drugs. Though these alginate beads can be prepared easily through simple and economic 
procedures, these beads suffer from low drug encapsulation and poor mechanical property in 
the intestinal pH, which lead rapid drug release. To minimize these limitations, ionically 
gelled alginate beads have been modified by various research groups. Currently, modified 
alginate beads using SA and plant-derived natural polysaccharide blends have been 
investigated to improve drug encapsulation, swelling, drug release, etc.  Most of these 
modified alginate beads were prepared using plant-derived natural polysaccharide blends 
with SA and using calcium chloride (CaCl2) as a cross-linker. Various calcium-ion induced 
alginate-based beads loaded with drugs were also investigated earlier. In the current 
communication, we aimed to develop controlled drug release Ca2+-ion induced alginate-okra 
gum (OG) blend beads by ionic-gelation cross-linking method using calcium chloride (CaCl2) 
as a cross-linker in an aqueous environment. 
Okra (Hibiscus esculentus, family – Malvaceae) is an annual plant cultivated 
throughout the tropical and subtropical areas of the world. The immature okra fruit is also 
used in folk medicine. OG obtained from okra fruit is composed of d-galactose,l-rhamnose 
and l-galacturonic acid. It is chemically inert, non-irritant, biodegradable and biocompatible. 
It is water-soluble and produces highly viscous solution with a slimy appearance. OG is 
already investigated as useful excipients in the development of various pharmaceutical 
formulations. The highly viscous property of OG leads the usefulness of it as a drug-release 
retarding polymer. Capecitabine is a prodrug that is selectively tumour-activated to its 
cytotoxic moiety, fluorouracil, by thymidine phosphorylase. Fluorouracil is further 
metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) 
and 5-fluorouridine triphosphate (FUTP), within normal and tumour cells. FdUMP inhibits 
DNA synthesis by reducing normal thymidine production, while FUTP inhibits RNA and 
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protein synthesis by competing with uridine triphosphate. The active moiety of capecitabine, 
fluorouracil, is cell cycle phase-specific (S-phase). 
In order to utilize the OG for the oral drug delivery, the development of other dosage 
forms, which is more convenient in administration, is demanded. Bead-type of OG gel has 
several advantages such as the facility of drug loading, reduction of the risk of dose dumping, 
and facility of dose adjustment besides the convenient administration. However, the stability 
of OG beads is lowered due to the isolation of gelled spheres in the dilute condition of GI 
track. The special coating process will improve the stability of OG beads and also allow the 
colon-specific release of gastric mucosal irritant drug. 
Specific Eudragit polymers have been developed for oral dosage forms with step-wise 
release of active ingredient in the digestive tract. Eudragit is insoluble below pH 5 and thus 
resistant to gastric fluid. By salt formation in the neutral to weakly alkaline medium of the 
intestinal fluid, the polymer dissolves step-wise at pH values above 6. These properties are 
what render Eudragit as the most popular material for enteric-coating and stabilizing agent 
for OG beads. 
In this study, factorial design based on response surface methodology(RSM) was introduced 
to optimize the preparation of OG beads.RSM is a useful statistical technique for formulation 
and process optimization, which is accomplished by studying the mutual interactions among 
the variables over a range of values in a statistically valid manner. OG beads were prepared 
by thermo sensitive gelation of OG aqueous solution and coated with Eudragit. In vitro drug 
release behavior of the Eudragit coated OG beads was carried out in gastro-intestinal pH (1.2, 
5.8 and 7.4). Invitro release kinetics models were applied to the study the release mechanism 
of the drug from beads.  
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PLAN OF THE WORK 
1. LITERATURE SURVEY   
2. PREFORMULATION STUDIES 
a. Solubility of the drug  
b. Drug and excipient compatibility 
c.  Standard graph of drug  
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6. SWELLING INDEX AT DIFFERENT pH 
7. INVITRO RELEASE STUDIES     
a. Preparation of Capecitabine loaded Sodium alginate and okra gum beads 
b. Eudragit coated Capecitabine loaded Sodium alginate and okra gum beads 
 
8. INVITRO RELEASE KINETICS 
a. Zero order kinetics 
b. First order kinetics 
c. Higuchi model of kinetics 
d. Hixson Crowel kinetics 
e. Korsmeyer-Peppas model for kinetics   
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DRUG AND EXCIPIENT PROFILE 
CAPECITABINE (72, 73) 
Structure: 
 
Figure: 3 STRUCTURE OF CAPECITABINE 
IUPAC Name: 
Pentyl [1-(3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1H pyrimidin-4-yl] 
carbamate 
Molecular weight: 
359.35 
Molecular Formula: 
C15H22FN3O6 
Melting point: 
110-121˚C 
LogP:  
0.4 
Solubility: 
It is soluble in water (2ymg/ml) 
Category: 
Antineoplastic 
T1/2:    
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Approximately 38-45 minutes 
Dose:  
The usual starting dose is 2,500mg/m2/day in two divided doses, 12 hours     apart. One cycle 
includes two weeks of treatment followed by one week without treatment. Cycles can be 
repeated every three weeks. 
BCS:  
 Class type III (High solubility, Low permeability) 
Pharmacokinetics: 
Absorption: 
Readily absorbed through GI tract (approximately 70%).Time to reach peak plasma 
concentration for Capectabine is approximately 1.5 hours and for 5-fluorouracil is 2 hours. 
Food decreased peak plasma concentration is 60% and area under curve is 35% for 
Capecitabine and decreased peak plasma concentration (Cmax) 4.3% and area under curve 
21% for 5-fluorouracil. Food delayed Tmax is 1.5 hours. 
Protein binding: 
Less than 60% protein binding (mainly albumin). 
Metabolism: 
Metabolized by thymidine phosphorylase to fluorouracil . 
Elimination: 
Capecitabine and its metabolites are predominantly excreted in urine. About 95.5% of 
administered Capecitabine dose is recovered in urine. Focal excretion is minimal (2.6%). The 
major metabolite excreted in urine is FBAL which represents 57% of the administered dose. 
About 3% of the administered dose is excreted in urine as unchanged drug. 
Mechanism of Action: 
Capecitabine is a prodrug that is selectively tumor-activated to its cytotoxic moiety, 
fluorouracil, by thymidine phosphorylase, an enzyme found in higher concentrations in many 
tumors compared to normal tissues or plasma. Fluorouracil is further metabolized to two 
active metabolites, 5-fluoro-2‟-deoxyuridine 5‟-monophosphate (FdUMP) and 5-
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fluorouridine triphosphate (FUTP), within normal and tumor cells. These metabolites cause 
cell injury by two different mechanisms. First FdUMP and the folate cofactor, N5-10-
methylenetetrahydrofolate, bind to thymidylate synthase (TS)to form a covalently bound 
ternary complex. This binding inhabits the formation of thymidylate from 2‟-deaxyuridylate. 
Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the 
synthesis of DNA, therefore a deficiency of this compound can inhabit cell division. 
Secondly, nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of 
uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere 
with RNA processing and protein synthesis through the production of fraudulent RNA. 
Indications and usage: 
Capecitabine is a nucleoside metabolic inhibitor with anti-neoplastic activity. It is used in the 
treatment of adjuvant colon cancer Stage III Duke‟s C-used as first-line monotherapy. 
Metastatic colon rectal cancer  
 First line as monotherapy alone is preferred. 
Metastatics breast cancer  
 Asmonotherapy, if the patient has failed paclitaxel based treatment, and if 
anthracycline based treatment, and if anthracycline based treatment has either failed 
or cannot be continued the other reasons. 
 Used in combination with docetaxel, after failure of anthracycline based treatment. 
Adverse reactions: 
 Most common adverse reactions are: 
Cardiovascular  : EKG changes, myocardial infarction, angina. 
Dermatological   : Hand and foot syndrome. 
Gastrointestinal  : Diarrhea, Nausea, stomatitis. 
Heamatological  : Neutropenia, anemia and thrombocytopenia. 
Hepatic   : Hyperbilirubinemia. 
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Drug interaction: 
 Anticolagulants : May interact with warfarin and increase bleeding risk. 
 Phenytoin  : May inhibit cytochrome CYP2C9 enzyme, and therefore increase  
     levels of substrates such as Phenytoin and other substrates of  
     CYP2C9 
 Leucovorin : The concomitant use of Leucovorin increased the toxicity of  
      Capecitabine without any apparent advantage in response rate. 
Pharmacodynamic: 
Capecitabine is a fluoropyrimidine carbamate with antineoplastic activity indicated for the 
treatment of metastatic breast cancer and colon cancer. It is an orally administered systemic 
prodrug that has little pharmacologic activity until it is converted to fluorouracil by enzymes 
that are expressed in higher concentrations in many tumors. Fluorouracil it then metabolized 
both normal and tumor cells to 5-fluoro-2‟-deoxyuridine 5-„monophosphate (FdUMP) and 5-
fluorouridine triphosphate (FUTP) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
55 
POLYMER PROFILE 
SODIUM ALGINATE (73) 
Non-proprietary Names:  
BP  : Sodium Alginate        
PhEur  : Sodium Alginate       
USP-NF : Sodium Alginate   
Synonym:  
Alginatosodico, algin, alginic acid, sodium salt, E401, Kelcosol, Keltone, natriialginas, 
Protanal, sodium polymannuronate. 
Chemical Name   
Sodium alginate   
Functional category 
Stabilizing agent, suspending agent, tablet and capsule disintegrant, tablet binder, viscosity 
increasing agent 
Structural Formula: 
 
Figure: 4 Structure of Sodium Alginate 
Molecular Weight: 
216.121gm/mol. 
Description 
Sodium alginate occurs as an odorless and tasteless, white to pale yellowish-brown colored 
powder.   
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Solubility 
Practically insoluble in ethanol (95%), ether, chloroform, and ethanol/water mixtures in 
which the ethanol content is greater than 30%. Also, practically insoluble in other organic 
solvents and aqueous acidic solutions in which the pH is less than 3. Slowly soluble in water, 
forming a viscous colloidal solution. 
Viscosity 
Typically, a 1% w/v aqueous solution, at 20ºC, will have a viscosity of 20– 400 mPas (20–
400 cP). Viscosity may vary depending upon concentration, pH, temperature, or the presence 
of metal ions. Above pH 10, viscosity decreases.   
Incompatibilities 
Sodium alginate is incompatible with acridine derivatives, crystal violet, phenyl mercuric 
acetate and nitrate, calcium salts, heavy metals, and ethanol in concentrations greater than 
5%. Low concentrations of electrolytes cause an increase in viscosity but high electrolyte 
concentrations cause salting-out of sodium alginate; salting-out occurs if more than 4% of 
sodium chloride is present.   
Stability and storage condition 
Stable, the bulk material should be stored in an airtight container in a cool, dry place.   
Safety:  
It is generally regarded as a nontoxic and non-irritant material, although excessive oral 
consumption may be harmful.   
Application in pharmaceutical formulation or technology:  
Sodium alginate is used in a variety of oral and topical pharmaceutical formulations. In tablet 
formulations, sodium alginate may be used as both a binder and disintegrant, it has been used 
as a diluent in capsule formulations. Sodium alginate has also been used in the preparation of 
sustained-release oral formulations. In topical formulations, sodium alginate is widely used as 
a thickening and suspending agent in a variety of pastes, creams, and gels, and as a stabilizing 
agent for oil-in-water emulsions. Recently, sodium alginate has been used for the aqueous 
microencapsulation of drugs.   
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CALCIUM CHLORIDE (74) 
Non-proprietary Names 
 BP: Calcium Chloride Dihydrate, Calcium Chloride Hexahydrate 
 JP: Calcium Chloride Hydrate 
 PhEur: Calcium Chloride Dihydrate 
 Calcium Chloride Hexahydrate 
 USP-NF: Calcium Chloride 
Synonyms 
Calciichloridumdihydricum; calciichloridumhexahydricum. 
Chemical Name and CAS Registry Number 
 Calcium chloride anhydrous [10043-52-4] 
 Calcium chloride dihydrate [10035-04-8] 
 Calcium chloride hexahydrate [7774-34-7] 
 Empirical Formula and Molecular Weight 
 CaCl2 110.98 (for anhydrous) 
 CaCl2_2H2O 147.0 (for dihydrate) 
 CaCl2_6H2O 219.1 (for hexahydrate) 
Structure 
 
Figure: 5 Structure of calcium chloride 
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Functional Category 
Antimicrobial preservative; therapeutic agent; water-absorbing agent. 
Applications in Pharmaceutical Formulation or Technology 
1. The main applications of calcium chloride as an excipients relate to its dehydrating 
properties and, therefore, it has been used as an antimicrobial preservative, as a desiccant, 
and as an astringent in eye lotions. 
2. Therapeutically, calcium chloride injection 10% (as the dehydrate form) issued to treat 
hypocalcaemia. 
Description 
Calcium chloride occurs as a white or colorless crystalline powder, granules, orcrystalline 
mass, and is hygroscopic (deliquescent). 
Pharmacopeial Specifications 
Property  Limit  
pH 4.5-9.2  
Boiling point  >16008 ˚C (anhydrous)  
Density  0.835g/cm3 (Dihydrate)  
Melting point  7728˚C (Anhydrous)  
1768˚C (Dihydrate)  
309˚C (hexahydrate)  
Solidification temperature  28.5-308˚C  
Solubility  Freely soluble in water and ethanol  
Insoluble in diethyl ether and diethyl 
ether  
Stability and Storage Conditions 
Calcium chloride is chemically stable; however, it should be protected from moisture.Store in 
airtight containers in a cool, dry place. 
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Incompatibilities 
Calcium chloride is incompatible with soluble carbonates, phosphates, sulfates, andtartrates. 
 It reacts violently with bromine trifluoride, and a reaction with zinc releases explosive 
hydrogen gas. It has an exothermic reaction with water, and when heated to decomposition it 
emits toxic fumes of chlorine. 
Method of Manufacture 
Calcium chloride is a principal by product from the Solvay process. 
Safety 
Calcium chloride is used in topical, ophthalmic, and injection preparations. The pure form of 
calcium chloride is toxic by intravenous, intramuscular, intraperitoneal, and subcutaneous 
routes, and moderately toxic by ingestion, causing stomach and heart disturbances. It is a 
severe eye irritant and can cause dermatitis. 
Handling Precautions  
Observe normal precautions appropriate to the circumstances and quantity of the material 
handled. Calcium chloride is irritating to eyes, the respiratory system, and skin. Gloves, eye 
protection, respirator, and other protective clothing should be worn.  
Regulatory Status  
GRAS listed. Included in the FDA Inactive Ingredients Database (injections, ophthalmic 
preparations, suspensions, creams).Included in medicines licensed in the UK (eye drops; 
intraocular irrigation; vaccines; injection powders for reconstitution; nebulizer solution; oral 
suspension). 
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EUDRAGIT S – 100 (74) 
Synonym 
Eudragit; Methacrylic acid 
Non-proprietary Names 
NF: Methacrylic acid copolymer; Polymeric methacrylates 
Chemical Name 
Copolymers synthesized from dimethyl amino-ethyl methacrylate and other neutral 
lmethacrylic esters. 
Functional category 
Film former and tablet binder. 
Density 
 12.5; 0.825g/cm3 
Structure 
 
Figure: 6 Structure of Eudragit S 100 
Molecular Weight 
100,000 and approximately 135,000 
Description 
Polymethacrylates are film coatings and matrix structures based on polymericmethacrylates. 
They are synthetic cationic and anionic polymers of dimethyl amino ethylmethacrylates, 
methacrylic ratios. Type L (easily soluble in intestinal fluid) is 50% methacrylic acidand 
Type S(barely soluble in intestinal fluid) is 30% methacrylic acid; both areanionic polymers 
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of methacrylic acid and methacrylic acid esters in different ratios available as 12.5% solution 
in isopropanol without plasticizer (L 12.5, S 12.5); and as12.5% ready to use solution in 
isopropanol with 1.25% dibutylphthalate as plasticizer (L 12.5p, S 12.5p);colorless, with the 
characteristic odor of the solvent. 
Solubility 
1g of Eudragit L100 0r Eudragit S100 dissolves in 7g methanol, ethanol, in aqueous 
isopropyl alcohol and acetone, as well as in 1 N sodium hydroxide to give clear to slightly 
cloudy solutions. Eudragit L100 and Eudragit S100 are practically insoluble in ethyl acetate, 
methylene chloride, petroleum ether and water.  
Viscosity 
Eudragit S100= 29mm2/s  
Acid value 
Eudragit L100=316mgKOH/gDS 
Eudragit S 100=190mgKOH/gDS 
Incompatibilities 
Incompatibilities occur with acid and/or alkaline conditions depending upon which polymer 
is being used.  
Stability and storage condition 
Dry powder forms appear to be stable at room temperature. Dispersions are stable for about 1 
yr after manufacturing and stored at room temperature in tight containers protect against 
moisture.  
Safety 
Acute toxicity studies have been performed in rats, rabbits and dogs. No toxic effects were 
observed. Chronic toxicity studies were performed in rats over a period of 3 months. No 
significant changes were found in the animal organs.  
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MATERIALS 
List of materials and suppliers 
Table 2: List of materials used 
S.NO RAW MATERIALS MANFACTURER 
1. Capecitabine Sigma Aldrich 
2.  Eudragit S – 100 Yarrow Chem Products Mumbai, India 
3. Acetone Rolex laboratory reagent 
4. Ethanol Lobachemieloboratory and fine chemicals 
5. Sodium alginate S.D Fine Chemicals, Mumbai India 
6. Calcium chloride S.D Fine Chemicals, Mumbai India 
7. Ethanol Lobachemieloboratory and fine chemicals 
 
 
List of equipment‟s and manufacturer  
Table 3: List of instruments used 
S.NO INSTRUMENTS MANFACTURER 
1. Electronic balance Wensar 
2. Digital pH meter Elico 
3. Sonicator Vibro cell 
4. Dissolution apparatus Electrolab 
5. Magnetic stirrer Remi motors 
6. Mechanical shaker Technico lab 
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7. UV spectrometer Shimadzu, japan 
8. Fourier transit infra-red spectroscopy Thermo scientific Nicolet ISF 
9. Scanning electron microscopy JEOL 
10. Electronic microscope LW electronic microscopes 
11. Hot air oven Techno Lab 
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METHODS 
ISOLATION OF HIBISCUS ESCULENTUS (OG) (46) 
 
1 kg of unripe and tender Okra fruits 
 
 
Washed and sliced thinly using a knife 
 
 
Seeds were removed from sliced fruits 
 
 
Sliced mass was soaked in distilled water 
Over night 
 
 
After soaking, viscous gum is filtered out using muslin cloth 
 
 
To the viscous gum acetone was added to precipitate gum at a ratio of ratio of 3 parts of 
acetone to 1 part of the gum 
 
 
Then, the precipitate was dried at 40◦C. The dried film obtained was crushed to fine powder 
through sieve no. 120 and kept in air-tight desiccator. 
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Characterization of Okra gum: (46,48).  
Ash Values: As discussed by authors in previous publication ash values such as total ash, 
acid insoluble ash and water- soluble ash were determined using equation 1, 2, 3 respectively. 
Total ash value = ݓ݁݅݃ ݄ݐ݋݂ܽݏ ݄ݓ݁݅݃ ݄ݐ݋݂݌݋݈𝑦݉݁ݎ ×100   (1) 
 
Acid insoluble ash = ݓ݁݅݃ ݄ݐ݋݂ܽܿ݅݀݅݊ݏ݋݈ݑܾ݈݁ܽݏ ݄ݓ݁݅݃ ݄ݐ݋݂݀ݎ݅݁݀݌݋ݓ݀݁ݎ ×100  (2) 
 
Water soluble ash = ݓ݁݅݃ ݄ݐ݋݂ݓܽݐ݁ݎݏ݋݈ݑܾ݈݁ܽݏ ݄ݓ݁݅݃ ݄ݐ݋݂݀ݎ݅݁݀݌݋ݓ݀݁ݎ ×100  (3) 
 
Solubility behaviour: As already described by author‟s one part of dry mucilage powder was 
shaken with different solvents and further solubility was determined. 
 
pH of Mucilage: The mucilage was weighed and dissolved in water separately to get a 
1%w/v solution. The pH of solution was determined using digital pH meter as described by 
authors in previous publication. 
 
Surface Tension: The surface tension of the selected mucilage was determined by drop 
count method, using astalagmometer. The surface tension of the polymer has been reported to 
influence binding quality of the polymer. Surface tension was calculated as per equation 4. 
 
σsolution= σwater݉(ݏ݋݈ݑݐ݅݋݊ )݉(ݓܽݐ݁ݎ )   (4) 
 
Where, 
 σsolution– Surface tension of solution 
 σwater- Surface tension of water 
 m (solution)- Weight of solution 
 m (water)- Weight of water 
 
Viscosity: As described by authors viscosity of okra mucilage was determined using Oswald 
viscometer were calculated using equation 5. 
 S = w× ݐݏ𝜌ݏݐݓ𝜌ݏ     (5) 
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Where, 
 s- Viscosity of solution 
 w- Viscosity of water 
 t- Time 
 ρ- Density 
 
Loss on Drying: The test was carried out according to the procedure described by authors 
elsewhere. One gram of powder was weighed accurately in a weighing bottle and was dried 
in a hot air oven at 105°C and the weight was checked at intervals of 10min, until a constant 
weight was obtained. The percentage weight lost by the powder was calculated using 
equation (6). 
 
 Loss on drying = ݅݊݅ݐ݈݅ܽݓ݁݅݃ ݄ݐ−݂݈݅݊ܽ ݓ݁݅݃ ݄ݐ݅݊݅ݐ݈݅ܽݓ݁݅݃ ݄ݐ ×100 (6) 
 
Bulk Density and Bulkiness: It has been described by authors that inverse of bulk density is 
called as bulkiness. As per previous study accurately weighed quantity of (50 g) was 
introduced into a graduated measuring cylinder. The cylinder was fixed on the bulk density 
apparatus and the volume occupied by the powder was noted. Then, the powder was 
subjected to tapping in a bulk density apparatus until constant volume was obtained. The final 
volume (Bulk volume) was noted. Bulk density, tapped density and bulkiness were calculated 
using equations 7-9 respectively. 
 
 Bulk density = ݓ݁݅݃ ݄ݐ݋݂݌݋ݓ݀݁ݎܾ݈݁݊݀ݓ݁݅݃ ݄ݐ݋݂ܽ݌݌ܽݎ݁݊ݐݒ݋݈ݑ݉݁   (7) 
 
 Tapped density = ݓ݁݅݃ ݄ݐ݋݂݌݋ݓ݀݁ݎܾ݈݁݊݀ݐܽ݌݌݁݀ݒ݋݈ݑ݉݁   (8) 
 Bulkiness = 1ܾݑ݈݇݀݁݊ݏ݅ݐ𝑦     (9) 
 
True Density: Among various methods available for the determination of true density, liquid 
displacement method is the simplest method and was used in the present study. Acetone was 
selected as the liquid for displacement, because, mucilage is insoluble and heavy in acetone. 
This method has been used by many authors. 
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Powder Flow Property: Flow characteristics were measured by angle of repose as previous 
publication of authors. Same study was repeated here. Using the readings and the formula, 
the angle of repose was calculated using equation 10. 
 
Tan Ɵ = ݄/ݎ  (10) 
Where, 
 Ɵ- Angle of repose 
 h- Height of pile 
 r- Radius of pile 
 
Powder Compressibility (Carr’s Consolidation Index): This property is also known as 
compressibility. As described in previous publication finely powdered mucilage (5 g) was 
transferred into a measuring cylinder and calculations were done using bulk density 
apparatus. 
 
Particle Size Analysis: The particle size was determined by microscope. 
 
Characterization of Capecitabine 
Preformulation studies: 
Preformulation can be defined as an investigation of physical and chemical properties of a 
drug substance alone. The overall objective of preformulation studies is to generate 
information useful to the formulator in developing stable and bio available dosage forms. 
 Organoleptic properties 
 Solubility Studies 
Organoleptic properties: 
The organoleptic characters of the drug like colour, odor, taste and appearance play an 
important role in the identification of the sample and hence they should be recorded in 
descriptive terminology. 
Solubility studies: 
An excess of drug is suspended in 100ml of dissolution medium containing various 
concentrations of carriers in stopper flask and equilibrated by intermittent shaking for 72 hrs 
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maintained at 37±20c.The solution is filtered through whattman filter paper. A portion of 
filtrate is diluted suitably and analyzed by UV spectroscopy. 
Analytical Method Development 
Standard curve of drug was prepared in 0.1N HCl, 5.8 buffer and 7.4 buffer. 
Procedure: 
1. Preparation of stock solution: An accurately weighed 100 mg of Capecitabine was 
dissolved in 0.1N HCl, 5.8 phosphate buffer and 7.4 phosphate buffer separately and 
make up the volume up to 100 ml in a volumetric flask (Stock Solution: I, 1000 μg/ml). 
This was sonicated for 5 minutes. 
 
2. From this 10 ml of solutions were pipette out and make up the volume up to 100 ml 
(Stock Solution: II, 100 μg / ml). 
 
3. Then the aliquots were prepared, whose concentration ranging from 0 to 60μg/ml for 
0.1N HCl, 0 to 20μg/ml for 5.8 buffer and 0 to 20μg/ml  7.4 buffer and the absorbance 
was measured at wavelength of 303nm by using UV Spectrophotometer (Shimadzu, 
Model No: 2450) against the blank. 
Experimental design for statistical optimization (78) 
A total of seventeen trial Capecitabine -loaded alginate-OG blend beads were 
proposed by three factors and two responses factorial design and prepared by ionic-gelation 
cross-linking method. Three factors are SA (A), OG (B) and CaCl2 (C), which were varied at 
three different levels: low(−1), medium (0) and high (+1). Drug loading (%) and cumulative 
drug release after 12 h (%) were evaluated as responses. Matrix of the design including 
investigated factors, responses and levels are also shown in Table 4. The mathematical model 
generated by three factors and two responses factorial design is following ():  
Y0 = b0+b1A+b2B+b3C+b12AB+b13AC+b23BC+b23BC+b11A2+b22B2+b33C2 
Where Y is the response; b0 is a constant; b1,b2 and b3 are the coefficients translating the 
linear weight of A, B and C, respectively; b12 , b13 and b23 are the coefficients translating the 
interactions between the variables; and b11 , b22 and b33 of the coefficients translating the 
quadratic influence of A, B and C. Linear and second-order polynomials were fitted to the 
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experimental data to obtain the regression equations, and their observed and predicted 
responses are given in Table 11. One-way ANOVA was applied to estimate the significance 
of the model (p < 0.05). 
Table: 4 Design of experiment-levels of various process parameters 
 
Response variable: Y1 – Drug loading (%); Y2 – Drug release in 12HRS (%) 
Preparation of Capecitabine-loaded Ca2+-ion induced alginate-OG beads 
Capecitabine -loaded alginate-OG blend beads were formulated by ionic-gelation 
cross-linking method using CaCl2 as cross-linker in an aqueous environment. Briefly, SA and 
OG aqueous dispersions were prepared separately using distilled water and solutions of SA-
OG blends were prepared. These solutions of SA-OG blends were well mixed with stirring 
for 10 min at 1000 rpm using a magnetic stirrer (Remi Motors, India).(61) 
Afterwards, capecitabine was added to the single w/w emulsion of SA-OG blends. 
The ratio of drug to polymer was maintained 1:2 in all formulations and mixed thoroughly 
using a sonicator (Remi Motors, India).  
The resulting dispersions were extruded through a 21-G flat-tipped hypodermic 
needle into slightly agitated 100 ml of aqueous CaCl2 solutions containing 20% (w/v). Added 
droplets were retained in the CaCl2 solutions for 15 min. The wet beads were collected by 
decantation, washed two times with distilled water and dried at 37◦C in a hot air oven for 
overnight. The dried beads were stored in desiccators until used.  
  
 
 LEVEL USED 
FACTORS LOW (-1) MEDIUM (0) HIGH (+1) 
X1 – Sodium alginate concentration 
(%w/v) 
2 4 6 
X2 - OG concentration (%w/v) 2 4 6 
X3 – Cross linking concentration (%w/v) 5 10 15 
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Preparation of enteric-coated OG beads(79) 
The OG beads prepared above were transferred into ethanol solutions of Eudragit S 100 at 
various concentrations of 2.5, 5.0, and 7.5%, and coated for 30 min with stirring (500 rpm). 
The resulting coated-OG beads were filtered and air dried. This coating process was repeated 
five times. 
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Figure: 7 Method of preparation of beads 
 
CaCl2 
Aqueous solutions was 
dispersed by 21G flat-
tipped hypodermic 
needleneedle 
Prepared beads 
were decanted 
after 15 mins 
Decanted beads were 
transferred to Eudragit 
solution.  
Allow to stand it 
for 30 minutes 
and filter off the 
coated beads 
CP+SA+OG 
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Characterization of beads(61) 
Determination of Drug Loading 
Accurately weighed 100 mg of Capecitabine-loaded alginate-OG blend beads were 
taken separately and were crushed using pestle-mortar. The crushed powders were placed in 
500 ml of phosphate buffer, pH 7.4, and kept it overnight followed by sonication for 15 min 
in a sonicator (Vibra Pvt. Ltd., India). The polymer debris formed after disintegration of 
beads was removed filtering through Whatman® filter paper (No. 40).The drug content in the 
filtrate was determined using a UV-VIS spectrophotometer (Shimadzu, Japan) at 276 nm. 
DEE of beads was calculated using this following formula: 
DL = Actual  drug  content  in  beads  
Theoretical  drug  content  in  beads
 × 100. 
Bead size measurement  
 The diameters of dried beads were measured using Veriner calipers having an 
accuracy of 0.001 mm. Dried beads were taken and inserted in between the space of two 
metallic plates. Diameters of resultant beads were displayed in the digital screen of the 
previously calibrated equipment. The average size was then calculated by measuring the 
diameter of 3 sets of 20 beads from each batch. 
SEM analyses  
 The surface morphology of the formulated beads was analyzed by scanning electron 
microscope (SEM) (JEOL, Japan). Beads were gold coated by mounted on a brass stub using 
double-sided adhesive tape and under vacuum in an ion sputter with a thin layer of gold (3–5 
nm) for 75 s. SEM photograph was taken at an acceleration voltage of 20 kV. 
Differential scanning calorimetry (DSC) 
 The DSC thermograms of the pure drug, drug-loaded micro beads and polymers were 
obtained using the Perkin Elmer JADE DSC system, to identify any interaction between the 
components of formulations. 
FTIR spectroscopy analyses 
 Samples were reduced to powder and analyzed as potassium bromide pellets by using 
an FTIR spectroscope (Perkin Elmer, USA).Each sample was mixed with potassium bromide 
at a ratio of 1:9 and converted into pellet at 100 kg pressure using a hydraulic press pellet 
 
73 
technique. Beads were placed in the sample holder and spectral scanning was taken in the 
wavelength region between 3800 and400 cm−1. 
Evaluation of swelling behavior 
Swelling behavior evaluation of Capecitabine-loaded alginate-OG blend beads was 
carried out in 0.1 N HCL (pH 1.2) and phosphate buffer(pH 7.4). 100 mg beads were placed 
in vessels of dissolution apparatus (Campbell Electronics, India) containing 500 ml respective 
media. The experiment was carried out at 37 ± 1◦C under 50 rpm paddle speed. At pre-
determined time intervals, swelled beads were taken out from the solution using stainless 
steel grid; excess surface liquid was removed gently without pressing hard and the weight 
was recorded using electronic microbalance (Model BL-220H, Shimadzu, Japan). Swelling 
index was determined using the following formula:  
Swelling index (%) =Weight  of  beads  after  swelling − Dry  weight  of  beads
Dry  weight  of  beads
 × 100 
In vitro drug release study 
 The in vitro release of Capecitabine-loaded alginate-OG blend beads was tested using 
a dissolution apparatus USP/BP/IP (Campbell Electronics, India). The baskets were covered 
with 100-mesh nylon cloth to prevent the escape of the beads. The dissolution was measured 
at37 ± 1◦C under 50 rpm speed. Accurately weighed quantities of Capecitabine-loaded OG-
alginate beads equivalent to 100 mg Capecitabine were added to900 ml of 0.1 N HCL (pH 
1.2). The test was carried out in 0.1 N HCL for 2 h, and then, continued in phosphate buffer 
(pH 7.4) for next6 Hrs. 5 ml of aliquots were collected at regular time intervals, and the same 
amounts of fresh dissolution medium were replaced into dissolution vessel. The collected 
aliquots were filtered, and suitably diluted to determine the absorbance using a UV-VIS 
spectrophotometer (Shimadzu, Japan) at 276 nm. 
Analysis of in vitro drug release kinetics and mechanism 
 The in vitro drug release data were evaluated kinetically in important mathematical 
models: 
Zero-order model: Q = kt + Q0; 
First-order model: Q = Q0ek.t; 
Hixson–Crowell model: Q1/3= kt + Q01/3; 
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Higuchi model: Q = kt0.5. 
Korsmeyer–Peppas model: Q = ktn;  
where Q = drug released amount in time t, Q0= start value of Q; k = rate constant, a = time 
constant, b = shape parameter and n = release exponent, indicative of drug release 
mechanism. The accuracy of these models was compared by calculation of squared 
correlation coefficient (R2) using Kinet DS 3.0 Rev. 2010 software. Again, the Korsmeyer–
Peppas model was employed in the in vitro drug release behavior analysis of these 
formulations to distinguish between competing release mechanisms: Fickian release 
(diffusion-controlled release), non-Fickian release (anomalous transport), and case-II 
transport(relaxation-controlled release). When n is ≤0.43, it is Fickian release. The n-value 
between 0.43 and 0.85 is defined as non-Fickian release. When, n is ≥0.85, it is case-II 
transport. 
Statistical analysis  
Statistical optimization was performed using Design-Expert10 software (Stat-Ease Inc., 
USA). All measured data are expressed as mean ± standard deviation (S.D.) and analyzed 
using Bio Stat version 10 2009 for Windows software. 
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RESULT AND DISCUSSION 
Characterization of Okra gum (61) 
After extraction and further precipitation by acetone the yield of mucilage was 
50.44% w/w obtained. The isolated sample was subjected to identification. The results for 
loss of drying showed value of 9.917%. This indicated that mucilage is hygroscopic in nature 
and need to be stored in   air-tight containers. In solubility behavior of okra mucilage was 
found to be soluble in warm water, slightly soluble in cold water and insoluble in benzene, 
ether, chloroform, n-butanol, ethanol, acetone, glycerin, paraffin. Surface tension of 0.25% 
w/v solutions of mucilage was found to be 0.0405 joule/m. Other phyto-constituents were 
absent in the 2 isolated powder, pH of 1% solution was found to be 7.5. Irregular particles 
size was found to be 52.50µm. Result obtained of okra mucilage and observed that mucilage 
is brownish color, odorless, tasteless, rough and irregular in shape. Ash values were 
calculated to characterize mucilage; total ash, acid insoluble ash and water soluble ash were 
found 7.53%, 0.93% and 4% respectively. Physical characterization of mucilage was carried 
out for bulk density and bulkiness, true density, total porosity, powder flow behaviour. The 
bulkiness value indicated that powder is „heavy‟ in nature. Result obtained in micromeritic 
characterization of mucilage was shown in Table 5. 
Table: 5 Micromeritic study data of mucilage 
S. No Parameters Values 
1 Angle of repose (º) 26.22 
2 Carr‟s index (%) 74.68 
3 True density (gm/ml) 2.74 
4 Bulk density (gm/ml) 0.637 
5 Bulkiness (ml/g) 1.34 
6 Mean particle size (µ) 54.41 
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Characterization of Capecitabine 
Table: 6Physical properties of capecitabine 
S. No Description Result 
1. 
2. 
3. 
4. 
5. 
Colour 
Odor 
Appearance 
Melting point 
Solubility 
White 
Odorless 
Powder 
116-117ºC 
Soluble in water, ethanol, >60% dimethyl form 
amide, marginally soluble in >40% methanol 
 
Standard curve of Capecitabine in 0.1N HCL, 5.8 phosphate buffer, 7.4 phosphate 
buffer 
Table: 7 Calibration curve of Capecitabine in 0.1N HCL 
Concentration 
(mcg/ml) 
Absorbance (nm) 
0 0 
10 0.165 
20 0.332 
30 0.49 
40 0.663 
50 0.823 
60 0.997 
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Figure: 8Calibration curve of Capecitabine in 0.1N HCL 
 
Table: 8 Calibration curve of Capecitabine in 5.8 phosphate buffer 
Concentration 
(mcg/ml) 
Absorbance (nm) 
0 0 
10 0.468 
12 0.568 
14 0.662 
16 0.765 
18 0.862 
20 0.961 
 
y = 0.016x - 0.001
R² = 0.999
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Figure: 9 Calibration curve of Capecitabine in 5.8 phosphate buffer 
 
 
 
Table: 9 Calibration curve of Capecitabine in 7.4 phosphate buffer 
Concentration (mcg/ml) Absorbance (nm) 
0 0 
10 0.404 
12 0.488 
14 0.572 
16 0.655 
18 0.748 
20 0.826 
 
y = 0.048x - 0.005
R² = 0.999
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Figure: 10Calibration curve of Capecitabine in 7.4 phosphate buffer 
 
Optimization of CP-loaded alginate-OG blend beads(80) 
According to Box – Behnken factorial design, various Capecitabine loaded alginate 
okra blended beads were prepared using Ca2+ ion using ionic gelation cross linking method. 
The matrix of the design including three factors (sodium alginate concentration, OG 
concentration, cross linking concentration) and two responses (drug loading, drug release) 
represented in Table 10.  The seventeen trial runs with respect to value responses were fitted 
into the design to get the model equation for responses. The results suggested that two 
quadratic equations involving individual main factors and interaction factors. The results of 
experimental design shown in Table 10 and it indicates that this model were significant for all 
response parameters. The model equation for the response Y1 (drug loading) and response Y2 
(drug release) is shown below. 
Y1=64.00+6.31A+10.67B+2.99C-7.19A2-8.16B2-3.84C2-0.15AB-0.025AC+1.50BC 
Y2=97.40+15.00A+0.50B-8.00C-15.08A2-19.58B2-12.07C2-2.75AB+7.75AC-1.75BC 
y = 0.041x - 0.004
R² = 0.999
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Where A, B and C were represent the polymer concentration, amount of cross linking 
agent and drug concentration respectively. A positive value represents an effect that favours 
the optimization, while a negative value indicates an antagonistic effect. The values of A, B, 
and C were substituted in the equation to obtain the theoretical values of Y1. The predicted 
values and the observed values were found to be in good agreement. The effect of pair wise 
interaction of the parameters is depicted in the three dimensional graphs when the third 
parameter is kept constant. The optimum condition for the preparation of Capecitabine beads 
as evident from Figure 11 are 4% w/v of sodium alginate concentration, amount of cross 
linking agent 10% w/v and 4%w/v OG concentration.  
Therefore the optimum procedure was determined to be the owing Briefly, SA and 
OG aqueous dispersions were prepared separately using distilled water and solutions of SA-
OG blends were prepared. These solutions of SA-OG blends were well mixed with stirring 
for 10 min at 1000 rpm using a magnetic stirrer (Remi Motors, India). Afterwards, 
Capecitabine was added to the single w/w emulsion of SA-OG blends. The ratio of drug to 
polymer was maintained 1:2 in all formulations and mixed thoroughly using a homogenizer 
(Remi Motors, India). The resulting dispersions were extruded through a 21-G flat-tipped 
hypodermic needle into slightly agitated 100 ml of aqueous CaCl2 solutions containing 10% 
w/v. Added droplets were retained in the CaCl2 solutions for 15 min. The wet beads were 
collected by decantation, washed two times with distilled water and dried at 37◦C in a hot air 
oven for overnight. The dried beads were stored in desiccators until used. 
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Table: 10Experimental runs and observed values of responses for Box-Behnken design  
  INDEPENDENT 
VARIABLES 
DEPENDENT VARIABLES 
     ACTUAL PREDICTED 
RUNS BATCH A B C Y1 Y2 Y1 Y2 
1. F1 0 0 0 63.52 96.89 64.02 97.37 
2. F2 -1 1 0 54.81 51.60 55.16 51.23 
3. F3 1 -1 0 43.03 80.74 42.61 80.17 
4. F4 1 0 1 62.18 89.59 62.93 89.11 
5. F5 -1 0 1 48.45 41.03 48.35 40.45 
6. F6 1 1 0 64.72 72.46 65.28 72.15 
7. F7 0 1 -1 58.18 81.05 57.74 80.63 
8. F8 -1 0 -1 43.64 67.13 43.23 67.76 
9. F9 1 0 -1 57.88 84.50 58.65 85.12 
10. F10 -1 -1 0 32.42 48.11 32.84 48.69 
11. F11 0 0 0 63.52 96.89 64.02 97.37 
12. F12 0 0 0 63.52 96.89 64.02 97.37 
13. F13 0 1 1 66.67 56.68 67.37 56.14 
14. F14 0 0 0 63.52 96.89 64.02 97.37 
15. F15 0 0 0 63.52 96.89 64.02 97.37 
16. F16 0 -1 1 44.75 56.31 44.05 55.62 
17. F17 0 -1 -1 39.92 71.84 40.46 72.49 
 
Response variable: Y1 – Drug loading (%); Y2 – Drug release in 12HRS (%) 
The influences of independable factors on dependable responses investigated (here, DL, and 
DR12h) were further elucidated and analyzed by response surface methodology (RSM). RSM 
is an alternate statistical approach, which is able to represent the effect of interaction between 
different independable factors. The main advantages of the RSM are the reduced numbers of 
experimental trials needed to evaluate multiple parameters and their interactions and it is 
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useful for developing, improving and optimizing process.The 3-dimensional response surface 
plot relating DL depicts increasing the values of OG (B) as well as decreasing the values of 
SA (A) and increasing CaCl2 concentration (C) (Figs. 11, 12 and 13 respectively). However, 
an increase in DR12hvalues with the increasing OG(B) and decreasing SA(A) and increasing 
CaCl2 concentration (C) is indicated by the 3-dimensional response surface plot relating DL 
and  DR12h (Figs. 14, 15 and 16, respectively). 
 
Figure:11 Three dimensional response surface plots relating % drug loading between okra 
gum and sodium alginate 
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Figure: 12 Three dimensional response surface plots relating % drug loading between 
Calcium chloride and sodium alginate 
 
Figure: 13 Three dimensional response surface plots relating % drug loading between okra 
gum and Calcium chloride 
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To develop a new formulation with the desired responses, numerical optimization 
technique was employed using the desirability approach. To get the desired optimum 
responses for CP-loaded alginate-OG blend beads, factors were restricted to2 ≤ A ≤ 6%, 2 ≤ 
B ≤ 6% and 5 ≤ C ≤ 15%whereas the desirable ranges of responses were restricted to 32 ≤ DL 
≤ 67(%) and 40 ≤DR12h(%) ≤ 97%under comprehensive evaluation of the feasibility search 
and subsequently exhaustive grid searches. 
 The optimal values of responses were obtained by numerical analysis using the 
Design-Expert 10.0.6.1 software based on the criterion of desirability. The overlay plot 
indicating the region of optimal process variable settings was presented in Fig. 11-16. In 
order to evaluate the optimization capability of these models generated according tothe 
results of 32-factorial design, optimized Ca2+-ion induced CP-loaded alginate-OG blend beads 
were prepared by ionic-gelation cross-linking were prepared using one of the optimal process 
variable settings proposed by the design. The selected optimal process variable setting used 
for the formulation of optimized CP-loaded alginate-OG blend beads. Table 10 lists the 
results of experiments with predicted responses by the mathematical models and those 
actually observed. The optimized CP-loaded alginate-OG blend beads (F-1) showed DL 
of64.02 ± 1.58% and DR12h of 97.32 ± 2.83% with small error-values(−1.82 and 2.85, 
respectively). 
 
Figure: 14Three dimensional response surface plots relating % drug release between okra 
gum and sodium alginate 
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Figure: 15 Three dimensional response surface plots relating % drug release between calcium 
chloride and sodium alginate 
 
Figure: 16 Three dimensional response surface plots relating % drug release between calcium 
chloride and Okra gum 
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Table: 11Regression analysis for response Y1 and Y2 
Model R-squared Adjusted 
R-squared 
Predicted 
R-squared 
SD Remarks 
Response (Y1) 
1. Linear 
2. Second order 
3. Quadratic 
4. Cubic 
 
0.6688 
0.6735 
0.9915 
1.0000 
 
0.5924 
0.4776 
0.9806 
1.0000 
 
0.2611 
-0.1316 
-1.3871 
N/A 
 
7.04 
7.97 
1.54 
8.944 
 
- 
- 
Suggested 
- 
Response (Y2) 
1. Linear 
2. Second order 
3. Quadratic 
4. Cubic 
 
0.3717 
0.4171 
0.9854 
0.9998 
 
0.2267 
0.0673 
0.9667 
0.9992 
 
0.0593 
-0.4376 
0.7697 
N/A 
 
17.35 
19.05 
3.60 
0.55 
 
- 
- 
Suggested 
- 
 
Table: 12 Summary of ANOVA for response parameters 
Source Sum of square d.f Mean square F value p-value 
Prob>F 
For D.L (%) 
 
Model 
A 
B 
C 
AB 
AC 
BC 
A2 
B2 
C2 
 
 
 
1929.75 
318.91 
911.43 
71.40 
0.093 
2.500 
9.00 
217.56 
280.58 
62.11 
 
 
9 
1 
1 
1 
1 
1 
1 
1 
1 
1 
 
 
214.42 
318.91 
911.43 
71.40 
0.093 
2.500 
9.00 
217.56 
280.58 
62.11 
 
 
90.85 
135.12 
386.17 
30.25 
0.039 
1.059 
3.81 
92.18 
118.88 
26.32 
 
 
<0.0001 
<0.0001 
<0.0001 
0.0009 
0.8483 
0.9749 
0.0918 
<0.0001 
<0.0001 
0.0014 
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For D.R (%) 
 
Model 
A 
B 
C 
AB 
AC 
BC 
A2 
B2 
C2 
 
 
 
 
6135.42 
1800.00 
2.00 
512.00 
30.25 
240.25 
12.25 
956.87 
1613.39 
613.92 
 
 
 
9 
1 
1 
1 
1 
1 
1 
1 
1 
1 
 
 
 
681.71 
1800.00 
2.00 
512.00 
30.25 
240.25 
12.25 
956.87 
1613.39 
613.92 
 
 
 
52.61 
138.92 
0.15 
39.51 
2.33 
18.54 
0.95 
73.85 
124.52 
47.38 
 
 
 
<0.0001 
<0.0001 
0.7061 
0.0004 
0.1704 
0.0035 
0.3633 
<0.0001 
<0.0001 
0.0002 
 
DRUG LOADING 
Drug loading of Capecitabine -loaded alginate-OG blend beads was found 67%. It 
was found that the drug loading in these beads was increased with decreasing concentration 
of SA (A)and increasing the concentration of OG (B) and increasing concentration of 
CaCl2(C) in cross-linking solutions. Increased drug loading with increasing OG might be due 
to increase in viscosity of the polymer-blend solutions with decreasing concentration of SA. 
This could have been prevented drug leakage to the cross-linking solution. Again, the drug 
loading in these beads was increased with increasing CaCl2 concentration in cross-linking 
solutions and this could be due to high degree of cross-linking. The high degree of Ca2+-ion 
induced cross-linking of alginate forms insoluble dense matrices, which results more drug 
loading in these beads. The Capecitabine -loaded alginate-OG blend beads prepared using 
lower CaCl2 concentration might have larger pores due to insufficient cross-linking and/or 
drug leaching through the pores. The insufficient cross-linking and/or drug leaching through 
the pores could result in lower drug loading. (85) 
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BEADS SIZE (83) 
The average bead diameter of Capecitabine-loaded alginate-OG blend beads was 
within the range of 1.016mm. Increase in the average size of these beads was found with the 
decreasing of SA. This could be attributed due to the increase in viscosity of polymer-blend 
solution with incorporation of increasing OG that in turn increased the droplet size of 
polymer-blend solutions to the cross-linking solutions during preparation. With the increasing 
amount of OG in the polymer-blends, the number of free sites available for cross-linking 
could be less so that the bead sizes with decreasing SA. The decrease in bead size of 
Capecitabine-loaded alginate-OG blend beads was observed, when concentrated CaCl2 
solutions were used for cross-linking. This could be due to shrinkage of polymeric-gel by 
higher degree of cross-linking. The shrink-age of the alginate-containing polymeric gel under 
the influence of concentrated CaCl2 solutions can be attributed that the Ca2+-ions penetrate 
the interior of alginate-OG blend droplets and water is squeezed out of the interior of 
droplets, which results shrinkage of beads. When the polymer concentration increased, the 
release percentage increases initially followed by decrease in drug release. The low release of 
the drug from the beads at higher polymer concentration may be due to delayed swelling of 
the beads with larger particle size formation. 
SURFACE MORPHOLOGY 
The surface morphology of Capecitabine-loaded alginate-OG blend beads was 
visualized by SEM and is presented in Fig. 17-19. The surfaces of these beads were appeared 
to have rough with characteristic large wrinkles and cracks, as it was evident from the SEM 
photographs. This might be caused by partly collapsing the polymeric gel network during 
drying. Moreover, few polymeric derbies and drug crystals were seen on the bead surface. 
Presence of polymeric derbies on the bead surface could be due to the simultaneous gel bead 
preparation and formation of the polymer blend matrix; whereas the presence of drug crystals 
on the bead surface might be formed as a result of their migration along with water to the 
surface during drying. 
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Figure: 17 SEM of Capecitabine loaded alginate- okra gum beads 
 
 
 
 
Figure: 18 SEM of Eudragit coated Capecitabine loaded alginate –okra gum beads 
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Figure: 19 SEM analyses shows the surface is porous and wrinkled  
FT-IR 
The FTIR spectra of SA, Eudragit, isolated OG, optimized Capecitabine-loaded 
alginate-OG blend beads and pure Capecitabine are shown in Fig.20 to 24. 
In the FTIR spectrum of SA, the characteristic peaks were appeared 1416 cm-1 and 
1616 cm−1, for symmetric and asymmetric –C=O stretching vibrations of -COO−anions, 
respectively. In addition, a wideband at 3441 cm−1was appeared due to the -OH stretching 
vibrations Fig.21.  
The spectrum of isolated OG showed an identical small peak at 1411 cm−1due to –C- 
H bend, a small peak at 1726 cm−1due to –C=O stretch, peak at 2928 cm−1due to –C- H 
stretch and a broad band at 3419 cm−1due to -OH stretching vibrations Fig. 22.  
FTIR spectrum of Eudragit S-100 showed the peak at 2953.9 cm–1 due to presence of 
O–H (carboxylic acid), at 1450.7 cm–1 due to -CH3 bend, and at 1731.2 cm–1 due to the 
presence of C = O (ester). 
In the spectrum of Capecitabine, there are sharp peaks at 1716, 1502, 3215, and 3520 
cm-1 corresponding to C=O stretching vibrations (pyrimidine carbonyl), N=O bending 
vibrations, N-H bending vibrations (tetra hydro furan), and -OH stretching vibrations 
respectively. These peaks were found in drug-loaded Eudragit coated -sodium alginate OG 
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beads. This confirms that no chemical interaction was found between the drug and polymers, 
thus confirming drug compatibility with these excipients. 
 
Figure: 20 FT-IR Spectra of Capecitabine Drug 
 
 
Figure: 21 FT-IR Spectra of Alginate 
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Figure: 22 FT-IR Spectra of Okra gum 
 
 
Figure: 23 FT-IR Spectra of Eudragit S 100 
 
 
Figure: 24 FT-IR Spectra of Eudragit Coated alginate OG beads 
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SWELLING STUDIES 
The swelling behavior of optimized Ca2+-ion induced CP-loaded alginate-OG blend beads (F-
1) was evaluated in both acidic pH(0.1 N HCl, pH 1.2) and alkaline pH (phosphate buffer, pH 
7.4). The results of swelling are shown in Fig. 25. Initially, the swelling index of OG-alginate 
beads (F-1) was lower in acidic pH in comparison with that of in alkaline pH. Under acidic 
pH, swelling of ionically gelled alginate-based beads occurs narrowly, which could probably 
due to formation of insoluble alginic acid regions through proton-calcium ion exchange and 
followed by solvent penetration into the gel-network. Maximum swelling was noticed at 3 h 
in alkaline pH and after which, erosion and dissolution of beads observed. The swelling 
behavior of optimized Ca2+-ion induced CP-loaded alginate-OG blend beads (F-1) in alkaline 
pH could be explained by the ion exchanging between Ca2+-ions of the Ca2+-ion induced CP-
loaded alginate-OG blend beads and the sodium ions present in phosphate buffer, with the 
influence of calcium sequestrant phosphate ions. This could result disaggregation of OG-
alginate matrix structure leading to matrix erosion and dissolution of the swollen beads. The 
slow erosion of these beads could take place through slight degradation of polymeric-
backbone into smaller molecular weight components. The overall swelling results suggested 
that the pH-sensitive swelling properties of these alginate-OG blend beads might be suitable 
for intestinal drug delivery as these beads were found to get rapidly dissolved in the higher 
pH prevailing in the intestine. 
 
Figure: 25Swelling studies of beads in graphical representation 
 
69
57
40
83
0
10
20
30
40
50
60
70
80
90
pH 1.2 pH 7.4
S
W
E
LL
IN
G
 I
N
D
E
X
 (
%
)
Alg beads Alg+Okra beads
 
94 
Differential Scanning Calorimetry (DSC) 
 The DSC thermogram of Capecitabine, drug loaded beads and polymers are shown in 
figure number 26(a) and 26(b). A sharp endothermic peak at 122.02º C was observed for pure 
Capecitabine corresponding to its melting point. There was no significant difference in 
thermogram of pure drug and drug loaded beads suggesting that, there is no interaction 
between drug and polymer.  
 
Figure: 26(a) Differential Scanning Calorimetry of Capecitabine 
 
Figure: 26(b) Differential Scanning Calorimetry of CP loaded Alginate OG blend beads  
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IN-VITRO DRUG RELEASE(82) 
Various Ca2+-ion induced CP-loaded alginate-OG blend beads (F-1 to F-13) showed 
prolonged in vitro CP release over 12 h(Fig. 27).The trace amount of drug (CP) release from 
these alginate-OG blend beads at this preliminary stage of the in vitro drug release study 
could probably be due to the surface adhered drug crystals of CP, which were evidenced in 
SEM photograph in bead surface morphology analysis (Fig. 19).Amounts of CP released 
from OG-alginate beads in the acidic pH (1.2) up to 2 h were less and might be due tothe 
shrinkage of alginate at acidic pH (as alginate is pH sensitive)and poor solubility of alginate 
in lower pH, which could slower the drug release from OG-alginate beads. After that CP 
release from OG-alginate beads was observed faster in alkaline pH (7.4), which might be due 
to the higher swelling rate of these beads in alkaline pH. In case of beads containing higher 
OG amount, the more hydrophilic property of polymer-blends could bind better with water to 
form viscous gel structure, which may block the pores on bead surfaces and sustain the drug 
release from the Ca2+-ion induced CP-loaded alginate-OG blend beads. The invitro drug 
release data reveals that drug release was observed in the acidic pH. In order to inhibit the 
drug release in acidic medium and target the drug release to colon the optimized batch of CP- 
loaded alginate OG blended beads (F1) were enteric coated with 2.5%,5% and 7.5% (F14, 
F15and F16) of Eudragit S-100 and further to the coated beads the invitro release was seen in 
both acidic and alkaline medium.  The data reveals that there was no drug release in acidic 
medium (upto 2hrs). The result indicates that drug was protected completely from upper GIT 
condition by a coating of Eudragit S100, because Eudragit polymer contain carboxyl group 
that ionize in an environment where pH is greater than 7. As ionization take place, integrity 
of film was disturbed and drug is released. At pH 7.4, membrane coating get dissolved and 
beads were exposed to dissolution media following which the polymer matrix swells and 
erodes releasing entrapped drug. In the case of uncoated OG beads, although suppressed 
under highly acidic condition due to the low solubility of the non-ionized form of 
Capecitabine, which exists at this pH (pKa of Capecitabine, 4.5), and the consequent 
partitioning of the drug into the polysaccharide chains of the gels, a more significant release 
of Capecitabine occurred in comparison with Eudragit-coated OG beads (Kawasaki et al., 
1999). However, at pH 7.4, Capecitabine was fully ionized and had a greater tendency to 
dissolve into the release medium. The higher release from the uncoated OG beads reflects the 
lower diffusion resistance of these core beads compared with that of the coated beads caused 
by the absence of a barrier against drug diffusion. 
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Figure: 27 Invitro- drug release study of CP loaded Alginate OG blend beads 
 
Figure: 28 Invitro- drug release study of Eudragit coated CP loaded Alginate OG blend beads 
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RELEASE KINETICS(82) 
The results of the curve-fitting into various mathematical models like zero-order, first-
order, Hixson–Crowell, Higuchi, and Korsmeyer–Peppas modelsare given in Table 13. When 
the respective R2of Eudragit coated CP loaded alginate-OG blend beads (F-14 to F-16) were 
compared, it was found to follow the Higuchi model (R2= 0.9772 to 0.986) over 12 h of in 
vitro drug release. In addition, Korsmeyer–Peppas model (R2= 0.9649 to 0.9792) and was 
found closer to the best-fit. The value of release exponent (n) determined from in vitro CP 
release data of various Eudragit coated CP-loaded alginate-OG blend beads ranged from 0.77 
to 1.231, indicating the super case-II transport mechanism controlled by swelling and 
relaxation of Eudragit coated CP loaded alginate-OG blend matrix. Results of release studies 
indicate that Eudragit S100 coated hydrogel beads offer a high degree of protection from 
premature drug release in simulated upper GIT conditions. A well coat of Eudragit S100 
delivers almost intact beads to colon, an environment rich in bacterial enzymes that degrade 
the polysaccharides and allow drug release to occur at desired site and can be a potential 
system for delivery of Capecitabine in cases of colon cancer. 
Table: 13 Model fitting of in-vitro release studies of Eudragit coated CP loaded 
Alginate OG blend beads 
 
 
MODELS FORMULATION CODES 
F14 F15 F16 
Zero order R2 0.9648 0.9644 0.9746 
First order R2 0.8139 0.9413 0.8671 
Hixson–Crowell R2 0.8976 0.8728 0.9129 
Higuchi R2 0.986 0.9893 0.9772 
Korsmeyer–
Peppas 
R2 0.9758 0.9792 0.9649 
n 0.7796 0.8099 1.231 
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Figure: 29 Zero order kinetics of CP loaded Alginate OG blend beads 
 
Figure: 30First order kinetics of CP loaded Alginate OG blend beads 
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Figure: 31 Higuchi order kinetics of CP loaded Alginate OG blend beads 
 
Figure: 32 Hixon- Crowel kinetics of CP loaded Alginate OG blend beads 
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Figure: 33 Korsmeyer-Peppas model of CP loaded Alginate OG blend beads 
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CONCLUSION 
Isolated OG was investigated as potential sustained drugrelease polymer-blends with SA in 
the development of controlleddrug release ionically gelled beads for oral use. Ca2+-ion 
induced CP-loaded alginate-OG blend beads was successfully prepared by Ca2+-ion induced 
ionic-gelation cross-linking method using CaCl2as cross-linker in an aqueous environment. 
Effects of polymer-blend ratio and cross-linker concentration on drug loading (DL) and 
cumulative drug release at 12 h (R12h) wereoptimized by factorial design. The DL of these 
alginate-OGbeads was found increasing with the decreasing of polymer-blendratio and 
increasing CaCl2concentration. However, an increase inR12hvalues with the increasing of 
polymer-blend ratio and CaCl2concentration was observed. Based on the numerical 
optimization, optimized beads were prepared using polymers concentration (i.e., SA and OG) 
= 4% and CaCl2 concentration = 10% w/v. Theseoptimized beads were of excellent 
combination of high drug loading (67.27 ± 3.58%) and suitable controlled drugrelease pattern 
over a prolonged period of 12h (97.73 ± 2.83%),which could possibly be advantageous in 
terms of advanced patientcompliance with reduced dosing interval.These Ca2+-ions induced 
CP-loaded alginate-OG blend beads also exhibited pH-dependent swelling, which could be 
advantageous for intestinal drug delivery. It was found that the drug release was shown in 
acidic pH to retard the release in acidic pH the prepared OG beads were coated with Eudragit 
S-100. Coated calcium alginate beads leads to prevent release in stomach pH and upper 
intestinal pH and rapid release of certain amount of drug on lower intestinal pH. The in vitro 
drug releasefrom these Eudragit coated OG-alginate beads was followed controlled-release 
(Higuchi model) pattern with super case-II transport mechanism. The result suggested that 
novel system might have potential carrier for colon targeted delivery of therapeutic drugs. 
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